 
Document  Type:  Study Protocol  
Official  Title:  A Phase 2b, Randomized, Double -blind, Placebo -controlled Study of 
NEOD001 in Previously Treated Subjects with Light Chain (AL) 
Amyloidosis who have Persistent Cardiac Dysfunction  
NCT  Number:  [STUDY_ID_REMOVED]  
Document  Date:  22 October  2017  
 
This protocol for Study NEOD001- 201 was  amended three times . 
Date of Original Protocol:  06 November 2015  
Date of Amendment 1:  28 June 2016  
Date of Amendment 2:  25 April 2017  
Date of Amendment 3:  22 October 2017  
 
The following key changes were made between amendments:  
Overview of Major/Substantial Changes  in Amendment 1:  
• Corrected and clarified eligibility criteria . 
• Clarified study population s, including the Modified Intent -to-Treat population and 
subjects considered to have AL amyloidosis -related  peripheral neuropathy.  
• Removed select study procedures to reduce patient burden and c larified  various study 
procedures, including the importance of consistency in administration of the 6- minute 
walk test . 
Overview of Major/Substantial Changes  in Amendment 2:  
• Added new and modified existing study endpoints.  
• Increased the number of subjects  
• Removed requirement for monthly collection of  additional coagulation indices  
• Corrected Inclusion Criterion #7 to align with existing stratification factor  
• Updated analysis populations and statistical analyses to align  with statistical analysis 
plan 
Overview of Major/Substantial Changes  in Amendment 3 : 
• Modified existing study endpoints based on updates to the statistical analysis plan 
• Updated statistical analyses to align with statistical analysis plan  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 3 of 111 INVESTIGATOR SIGNATURE PAGE  
 
Protocol Title:   A Phase 2 b, Randomized, Double-blind, Placebo-controlled Study of NEOD001  
in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Pe rsistent Cardiac 
Dysfunction Protocol Number:   NEOD001 -201 
Sponsor:    Prothena Therapeutics Limited  
Date of Original Protocol: 06 November 2015 
Date of Amendment 1:  28 June 2016 
Date of Amendment 2:  25 April  2017 
Date of Amendment 3:  22 October 2017 
    I have read the for egoing protocol and agree to conduct this study in accordance with the current 
protocol.    
Investigator Signature   Date  
 
Investigator Name  (Print ) 
 Please sign, date, and return  this form to  your Study Monitor. Please retain  a copy for  your 
study files.  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 4 of 111 TABLE OF CONTENTS  
TABLE OF CONTENTS  ..............................................................................................................4  
LIST OF TABLES  .........................................................................................................................7  
LIST OF FIGURES  .......................................................................................................................7  
1 INTRODUCTION............................................................................................................26  
1.1 Light Chain (AL) Amyloidosis ..............................................................................26  
1.2 Study Rationale  ......................................................................................................27  
1.3 Background on NEOD001 .....................................................................................28  
1.3.1  Nonclinical Safety  .................................................................................29  
1.3.2  Clinical Experience ...............................................................................31  
1.4 Rationale for Study Design and Dose Selection ....................................................33  
2 OBJECTIVES  ..................................................................................................................34  
3 STUDY PLAN  ..................................................................................................................35  
3.1 Study Des ign ..........................................................................................................35  
3.2 Endpoints ...............................................................................................................35  
3.2.1  Primary Efficacy Endpoint ....................................................................35  
3.2.2  Key Secondary Efficacy Endpoints  ......................................................35  
3.2.3  Additional Secondary Efficacy Endpoints ............................................35  
3.2.4  Exploratory Efficacy Endpoints ............................................................36  
3.2.5  Safety Endpoints  ...................................................................................38  
3.3 Number of Sites and Subjects ................................................................................38  
3.4 Randomization and Blinding .................................................................................38  
3.4.1  Randomization ......................................................................................38  
3.4.2  Emergency Unblinding .........................................................................38  
3.5 Safety Monitoring Committee  ...............................................................................39  
3.6 Estimated Study Duration  ......................................................................................39  
3.7 Definition of End of Study .....................................................................................39  
4 SELECTION, DISCONTINUATION, AND WITHDRAWAL OF SUBJECTS  ......40  
4.1 Inclusion Criteria  ...................................................................................................40  
4.2 Exclusion Criteria  ..................................................................................................42  
4.3 Early Treatment Discontinuation  ...........................................................................44  
4.4 Early Termination from the Study  .........................................................................45  
4.5 Replacement of Subjects  ........................................................................................45  
4.6 Termination of the Clinical Study ..........................................................................45  
5 TREATMENT OF SUBJECTS  ......................................................................................47  
5.1 Study Drug  .............................................................................................................47  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 5 of 111 5.1.1  Formulation, Packaging, and Labeling of NEOD001 ...........................47  
5.1.2  Shipping, Storage, and Handling of NEOD001 ....................................47  
5.2 Accountability and Return of Study Supplies ........................................................47  
5.3 Dosage, Preparation, and Administration ..............................................................48  
5.4 Dosage Adjustments ..............................................................................................49  
5.4.1  Withholding of Study Drug ...................................................................49  
5.4.2  Management of Suspected Systemic Infusion-
Related/Hypersensitivity Adverse Events  .............................................49  
5.4.3  Dose Reductions ...................................................................................50  
5.5 Treatment Compliance  ...........................................................................................50  
5.6 Prior and Concomitant Medication/Therapy .........................................................50  
5.6.1  Allowed (Concomitant) .........................................................................50  
5.6.2  Prohibited (Concomitant) ......................................................................50  
6 STUDY PROCEDURES  .................................................................................................52  
6.1 Evaluations by Visit  ...............................................................................................52  
6.1.1  Screening  ...............................................................................................52  
6.1.2  Treatment Visits  ....................................................................................54  
6.1.2.1  Month 1- Day 1  ...............................................................................55  
6.1.2.2  Months 2 through 12 – Day 1 (±5 Days)  .......................................57  
6.2 End of Study/Early Treatment Discontinuation (EOS/ETD):  30 (±5) Days AFTER Final Dose  ................................................................................................60
 
6.3 90-day Postdose Pregnancy Test ...........................................................................62  
6.4 Vital Status Follow -Up Phone Call........................................................................62  
6.5 Order of As sessments of Specific Tests .................................................................62  
6.6 Methods of Assessment  .........................................................................................63  
6.6.1  Safety .....................................................................................................63  
6.6.1.1  Clinical Laboratory Evaluations ....................................................63  
6.6.1.2  Vital Signs  ......................................................................................63  
6.6.1.3  Physical Examination .....................................................................64  
6.6.1.4  Echocardiograms............................................................................64  
6.6.1.5  12-Lead ECGs  ................................................................................64  
6.6.2  Efficacy  .................................................................................................64  
6.6.2.1  Organ Response (i.e., cardiac, renal, peripheral nerve) .................64  
6.6.2.2  Short Form-36v2® Health Survey (SF-36v2) ...............................64  
6.6.2.3  6-Minute Walk Test (6MWT) ........................................................65  
6.6.2.4  Kansas City  Cardiomyopathy Questionnaire (KCCQ) ..................65  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 6 of 111 6.6.2.5  Peripheral Neuropathy Assessment  ...............................................65  
6.6.3  Pharmacokinetics  ..................................................................................66  
6.6.4  Immunogenicity  ....................................................................................66  
7 ADVERSE EVENTS/SERIOUS ADVERSE EVENTS AND REPORTING  .............67  
7.1 Adverse Events —Definition  ..................................................................................67  
7.2 Adverse Events —Severity Rating  .........................................................................68  
7.3 Adverse Events —Causality Rating ........................................................................68  
7.4 Serious Adverse Events and Unexpected Adverse Events ....................................69  
7.4.1  Elective Procedures and Surgeries  ........................................................71  
7.4.2  Other Reportable Information ...............................................................72  
7.4.3  Disease Progression and Death  .............................................................72  
7.4.4  Serious Adverse Events—Reporting.....................................................72  
8 STATISTICAL M ETHODS AND CONSIDERATIONS  ............................................74  
8.1 Analysis Populations ..............................................................................................74  
8.2 Analysis of Study Population and Subject Characteristics ....................................74  
8.3 Analysis of Efficacy Endpoints .............................................................................75  
8.3.1  Primary Effic acy Analysis  ....................................................................75  
8.3.2  Key Secondary Efficacy Analyses  ........................................................75  
8.3.3  Additional Secondary Efficacy Analyses ..............................................76  
8.3.4  Exploratory Efficacy Analyses  .............................................................76  
8.4 Analysis of Safety Endpoints .................................................................................76  
8.5 Analysis of Other Endpoints ..................................................................................77  
8.5.1  Pharmacokinetics  ..................................................................................77  
8.5.2  Immunogenicity  ....................................................................................77  
8.6 Determination of Sample Size  ...............................................................................77  
8.7 Handling of Dropouts and Missing Data  ...............................................................77  
9 DATA RECORDING, RETENTION, AND MONITORING .....................................78  
9.1 Case Report Forms  .................................................................................................78  
9.2 Availability and Retention of Records ...................................................................78  
9.3 Quality  Control and Quality Assurance .................................................................78  
9.4 Subject Confidentiality  ..........................................................................................79  
10 ETHICAL AND LEGAL IS SUES  ..................................................................................80  
10.1  Ethical Conduct of the Study .................................................................................80  
10.2  Regulatory Approval  ..............................................................................................80  
10.3  Ethics Committee Approval ...................................................................................80  
10.4  Subject Informed Consent......................................................................................80  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 7 of 111 10.5  Subject Compensation for Adverse Effects on Health ..........................................81  
10.6  Protocol Amendments and Study Termination ......................................................81  
10.7  Finance, Insurance, and Indemnity  ........................................................................81  
10.8  Publication Policy  ..................................................................................................81  
11 REFERENCES  .................................................................................................................82  
12 APPENDICES  ..................................................................................................................84  
Appendix 1  Hematologic Response and Progression Criteria ..................................85  
Appendix 2  Examples of Highly Effective Contraception Methods ........................86  
Appendix 3  Revised International Myeloma Working Group (IMWG) 
Diagnostic Criteria for Multiple Myeloma  ............................................................87  
Appendix 4  Organ Response and Progression Criteria ............................................88  
Appendix 5  Neuropathy Impairment Scale – Lower Limbs  .....................................89  
Appendix 6  Visual Analog Scale – Pain Intens ity (VASPI) .....................................90  
Appendix 7  Eastern Cooperative Oncology Group (ECOG) Performance Status ...91  
Appendix 8  New York Heart Association (NYHA) Functional Classification  ........92  
Appendix 9  Short Form-36v2 Health Survey ...........................................................93  
Appendix 10  Kansas City Cardiomyopathy Questionnaire (KCCQ) .......................104  
Appendix 11  Laboratory Tests ..................................................................................108  
Appendix 12  Coagulation Indices  .............................................................................109  
Appendix 13  Schedule Of Events For Subjects Who Discontinue Study Drug 
Early but Agree to Return For Assessments After the ETD Visit .......................110  
 
LIST OF TABLES  
Table 1  Schedule of Assessments  ...........................................................................18  
Table 2  Common Terminology Criteria for Adverse Events (CTCAE) Grade 1-
5 for Peripheral Neuropathy and Neuropathic Pain ...................................66  
 
LIST OF FIGURES  
Figure 1  NEOD001 -201 Study Design ....................................................................21  
Figure 2  Proposed Mechanism of Action for NEOD001 .........................................28  
 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 8 of 111 PROTOCOL SYNOPSIS  
Title  A Phase 2 b, Randomized, Double-blind, Placebo-controlled 
Study of NEOD001  in Previously Treated Subjects with Light 
Chain (AL) Amyloidosis who have Persistent Cardiac 
Dysfunction 
Phase  2b 
Planned Number of Study Centers  Approximately 35 centers  globally 
Objective  The objective of this study is to determine the efficacy and safety of NEOD001 v ersus  placebo in subject s with AL 
amyloidosis who have persistent cardiac dysfunction. 
Study Design  This is a global, multicenter, Phase 2 b, randomized, double -
blind, placebo -controlled, two -arm, parallel -group efficacy  
and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who had a 
hematologic response (
Appendix 1) to  previous treatment 
for their amyloidosis (e.g., chemotherapy, autologous stem 
cell transplant [ ASCT ]) and have persistent cardiac 
dysfunction. 
Subject screening will occur during the 28 days prior to the 
first administration of study drug (i.e., Month 1- Day 1 
Visit) . If all eligibility requirements are met, the subject will 
be enrolled and Screening assessm ents will be completed. 
Screening assessments are listed in  Table 1 . 
Study visits will occur every 28 days based on scheduling from 
Month 1- Day 1. A ±5 -day window is allowed for visits starting 
after M onth 1. Subjects may receive up to 12 infusions of study 
drug. Subjects who discontinue study drug before the End of Study (EOS) Visit should have an Early Treatment 
Discontinuation (ETD) Visit 30 (±5) days after their final administration of study drug. 
Number of Subjects and Cohort Specifications  Up to 130  subjects will be enrolled and randomized ( 1:1) to 
NEOD001 or placebo. The randomization will be stratified according to:  
• Hematologic response; that is, c omplete response/ very 
good partial response (C R/VGPR ) vs partial response 
(PR) to first -line therapy  
• N-terminal pro -brain  natriuretic peptide (NT -proBNP) 
<1800 pg/mL vs ≥1800 pg/mL  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 9 of 111 Study Drug, Dose, and 
Mode of Administration  Study drug consists of NEOD001 24 mg/kg (dose not to exceed 2500 mg) or placebo. 
Study drug will be administered once every 28 (±5) days; a 
minimum of 21  days between doses is required. Subjects may 
receive up to 12  infusions of study drug. 
Study drug will be administered as an initial 120  (±10)- minute 
intravenous ( IV) infusion. If, in the opinion of the Investigator, 
the subject tolerates the initial infusion, subsequent infusions 
may be administered over 60 (±10) minutes . The length of the 
infusion may be extended over a longer period of time if and 
when it is clinically indicated  per Section 5.3. I n the case of a 
suspected systemic infusion-related reaction, follow 
instructions in Section 5.4.2. 
Subjects should be closely monitored for 90 (±10) minutes 
following completion of the study drug infusion. The Investigator may increase this standard monitoring time if 
deemed appropriate or per local standards. In the event of any 
clinical concerns or suspicious signs or symptoms after the infusion, the subject will remain under observation for as long 
as the Investigator deems it appropriate.  Beginning with the 
third infusion, the Investigator may decrease the monitoring 
time to no less than 60 minutes, if no infusion- related reactions 
were observed in the previous infusions and allowed per the IRB/ IEC. 
Control Group Normal saline will be used as the placebo control. 
Estimated Study and Treatment Duration  Each subject’s study duration may be up to 14 months, consisting of a Screening Phase (1 month), Treatment Phase 
(12 months), and the EOS Visit 30 (±5) days after the last dose. 
Subjects who complete the study and meet the eligibility criteria  will be considered for entry into a separate open- label 
extension study, during which subjects will receive  active 
treatment and may receive concurrent chemotherapy.  
Subject Eligibility 
Criteria  Inclusion Criteria  (subjects must meet all  of the following 
criteria):  
1. Age ≥18 years  
2. Confirmed diagnosis of systemic AL amyloidosis by the 
following: 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 10 of 111 o Histochemical diagnosis of amyloidosis determined by 
polarizing light microscopy of green birefringent 
material in Congo red -stained tissue specimens OR  
characteristic electron microscopy appearance  
AND  
o Confirmatory electron microscopy  OR 
immunohistochemistry OR mass spectrometry  of AL 
amyloidosis 
3. If the subject meets any  of the following criteria, c onfirm 
diagnosis of AL amyloidosis by mass spectrometry OR 
immunoelectron microscopy of amyloid material in  tissue 
biopsy:  
o Is black or African American  
o Is over 75 years of age (at time of diagnosis) with 
concurrent monoclonal gammopathy 
o Has a history of familial amyloidosis and has 
concurrent monoclonal gammopathy 
OR 
o If the subject m eets any of the above 3 conditions and 
has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencin g consistent with 
transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (
99mTc-DPD; Rapezzi et al, 2011), 
hydroxymethylenediphosphonate (99mTc-HMDP; 
Galat  et al, 2015), or pyrophosphate (99mTc-PYP; 
Bokhari et al, 2013) scintigraphy  
4. Cardiac involvement as defined by BOTH  of the 
following: 
o Past documented or presently noted clinical signs and 
symptoms supportive of a diagnosis of heart failure in 
the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 11 of 111 o Either an endomyocardial biopsy demonstrating  AL 
amyloidosis OR  an echocardiogram demonstrating a 
mean left ventricular wall thickness at diastole >12 mm 
in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening  
5. NT-proBNP ≥650 pg/mL and ≤ 5000 pg/mL  (i.e., 
≥76.7 pmol/L and ≤590 pmol/L)  
6. Received  at least one prior systemic chemotherapeutic 
regimen , which may include stem cell transplant, for AL 
amyloidosis 
7. Achieved at least a partial hematologic response (per 
Appendix 1) to  a first -line therapy resulting in a stable 
hematologic condition not currently  requiring additional 
active treatment against the plasma cell dyscrasia component of their AL disease 
8. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:   
o Absolute neutrophil count (ANC) ≥ 1.0 × 10
9/L 
o Platelet count ≥ 75 × 109/L 
o Hemoglobin ≥ 9 g/dL  
o Total bilirubin ≤ 2 × upper limit of normal (ULN) 
o Aspartate aminotransferase (AST) ≤ 3 × ULN  
o Alanine aminotransferase (ALT) ≤ 3 × ULN  
o Alkaline phosphatase (ALP) ≤5 × ULN (except for 
subjects with hepatomegaly and isozymes specific to 
liver, rather than bone) 
o  Estimated g lomerular f iltration r ate (eGFR) 
≥30 mL/min/1.73 m2 as estimated by the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation  
9. Systolic blood pressure 90-180 mmHg 
10. Distanc e walked during each  of the two Screening 6-
minute walk tests (6MWTs) is >100 meters  and 
<600 meters  
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 12 of 111 11. Women of childbearing potential (WOCBP) must have 
2 negative pregnancy tests during Screening, the second 
within 24 hours prior to the first administration of study drug and must agree to use highly effective physician-
approved contraception (
Appendix 2) from Screening to 
90 days following the last study drug administration  
12. Male subjects must be su rgically sterile or must agree to 
use highly effective physician -approved contraception 
(Appendix 2) from Screening to 90 days following the 
last study drug administration  
13. Ability to understand and willingness to sign an informed 
consent form prior to initiation of any study procedures 
Exclusion Criteria  (subjects must not meet any of the 
following criteria):  
1. Diagnosis of non-AL amyloidosis 
2. Meets the International Myeloma Working Group (IMWG) defin ition of Multiple Myeloma ( Appendix 3 ) 
3. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with 
subject’s ability to safely receive treatment or complete 
study assessments  
4. Myocar dial infarction, uncontrolled angina, uncontrolled 
ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6  months prior to the Month 1-
Day 1 Visit  
5. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area <1.0  cm
2) or severe congenital heart disease  
6. Electrocardiographic ( ECG ) evidence of acute ischemia 
or active conduction system abnormalities with the exception  of any of the following: 
o First degree atrioventricular (AV) block 
o Second degree AV block Type 1 (Mobitz Type  1/ 
Wenckebach type)  
o Right or left bundle branch block 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 13 of 111 o Atrial fibrillation with a controlled ventricular rate  
(uncontrolled [i.e., >110 bpm] ventricular rate is not 
allowed [determined by an average of three beats in Lead  II or 3 representative beats if Lead II is not 
representative of the overall E CG]) 
7. Has not recovered (i.e.,  equivalent to a Common 
Terminology Criteria for Adverse Events [CTCAE] 
≥Grade 2) from the clinically significant toxic effects of prior anticancer therapy . Exception:  subject s with prior 
bortezomib treatment may have CTCAE Grade 2 neuropathy. 
8. Received any of the following within the specified time 
frame prior to the Month 1- Day 1 Visit: 
o  Oral or intravenous antibiotics, antifungals, or 
antivirals within 1 week, with the except ion of 
prophylactic oral agents . Note:  I n the event that a 
subject  requires the chronic use of antivirals, Medical 
Monitor permission is required for entry into the study. 
o Hematopoietic growth factors, transfusions of blood or 
blood products within 1 week 
o Chemotherapy , radiotherapy, or other plasma cell 
directed therapy  within 6 months 
o ASCT within 12 months 
o Major surgery within 4 weeks 
o Planned major surgery or  organ transplant during the 
study 
o Any other investigational agent within 4 weeks 
o Prior treatment with NEOD001, 11-1F4, anti-serum 
amyloid  P [SAP] antibody ( exception:  allowed as part 
of established diagnostic procedures such as SAP  
scintigraphy) , or other investigational treatment 
directed at amyloid  
o Doxycycline within 6 weeks 
9. Active malignancy with the exception of any of the following: 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 14 of 111 o Adequately treated basal cell carcinoma, squamous cell 
carcinoma, or in situ cervical cancer  
o Adequately treated Stage I cancer from which the 
subject is currently in remission and has been in 
remission for ≥ 2 years  
o Low-risk prostate cancer with Gleason score <7 and 
prostate- specific antigen <10  mg/mL  
o Any other cancer from which the subject has been 
disease- free for ≥2 years  
10. History of Grade ≥ 3 infusion- related adverse events  
(AEs) or hypersensitivity to another monoclonal antibody 
11. History of severe allergy to any of the components of 
NEOD001 such as histidine/L-histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 
12. Currently known uncontrolled bacterial, viral, fungal, HIV, h epatitis B , or hepatitis  C infection  
13. Women who are breastfeeding  
14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of 
the study or which would, in the opinion of the 
Investigator, unacceptably increase the subject’s risk by participating in the study  
15. Unable or unwilling to adhere to the study- specified 
procedures and restrictions 
16. Subject is under legal custodianship 
17. Waldenström's macroglobulinemia and/or immunoglobulin M (IgM) monoclonal gammopathy 
Study Procedures and 
Assessme nts See Schedule of  Assessments ( Table 1 ) 
Endpoints  Primary  Efficacy Endpoint : 
• NT-proBNP best response from baseline through 12 
months of treatment 
Key Secondary Efficacy Endpoint s: 
• Change from baseli ne to 12 months of treatment in the 
Physical Component Score of the Short Form -36 Version 
2 (SF-36v2) 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 15 of 111 • Change from baseline to 12 months of treatment in the 
6MWT distance (meters)  
• NT-proBNP Slope over 12 months of treatment 
Additional Secondary Efficacy Endpoints: 
• Renal evaluable subjects : renal best response from 
baseline through 12 months of treatment  
• Peripheral neuropathy evaluable subjects: change from baseline to 12 months of treatment in NIS -LL total score  
• Hepatic evaluable subjects: hepatic best res ponse from 
baseline through 12 months of treatment 
 Exploratory Efficacy Endpoints: 
See Section  3.2.4 for a list of exploratory efficacy endpoints 
Safety Endpoints:  
Safety and tolerability of NEOD001 as assess ed by vital signs, 
12-lead ECGs, routine clinical laboratory assessments, AEs, 
and immunogenicity by measurement of anti- NEOD001 
antibodies  
Statistical Considerations and Methods  Analysis Populations:  
The Intent -to-Treat (ITT) Population will include all 
randomized subjects who receive any amount of study drug (NEOD001 or placebo). The ITT Population will be the 
primary population used for efficacy analyses. Treatment 
assignment will be based on the randomized treatment. The Safety Population will include all subjects who receive any 
amount of study drug (NEOD001 or placebo). The Safety 
Population will be the primary population used for safety analyses. Treatment assignment will be based on the randomized treatment.  
Efficacy Subset Populations: 
The Renal Ev aluable Population will include subjects who had 
renal involvement, i.e., proteinuria >0.5 g/24 hours (measured 
by 24 -hour urine total protein excretion), at baseline and at least 
one postbaseline assessment of proteinuria.  
The Peripheral Neuropathy Evalu able Population will include 
subjects who had peripheral nerve involvement at baseline 
(only if the subject had ascending sensorimotor neuropathy due 
to AL amyloidosis etiologies answered as yes) and had a 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 16 of 111 baseline NIS -LL total score of 2 or greater and at  least one 
postbaseline NIS- LL total score.  
The Hepatic Evaluable Population will include subjects who 
had hepatic involvement defined as >1.5 × ULN alkaline 
phosphatase at baseline and at least one postbaseline 
assessment of alkaline phosphatase.  
Primary E fficacy Analysis:  
The NT -proBNP best response rates in the two arms will be 
compared using the Cochran -Mantel -Haenszel  (CMH) test at 
the alpha=0.05 (two- sided) level of significance. The analysis 
will be stratified by the randomization stratification factors.  
Key Secondary Efficacy Analyses:  
NEOD001 and placebo will be compared on change from 
baseline in the SF -36v2 Physical Component Summary ( PCS) 
score after 12 months of treatment using a REML- based 
MMRM model including fixed effects for randomization st rata, 
treatment group, categorical time point, and the treatment group × time point interaction, and with the baseline value included as a covariate.  
The NEOD001 and placebo distributions of change from 
baseline in 6MWT distance (meters) after 12 months of treatment will be analyzed using a van Elteren test with stratification by randomization strata.   
The analysis of NT -proBNP  slope will be performed using a 
general linear mixed effects model  to compare the rate of 
change (i.e. , slope) of NT-proBNP over 12 months of treatment 
between treatment groups.  
For the primary and key secondary efficacy analyses, the 
overall 2 -sided level of significance will be alpha=0.05. The 
hypothesis testing of key secondary endpoints will be 
conducted in a sequential closed t esting gate -keeping procedure 
separately, provided the primary efficacy endpoint comparison is statistically significant at an alpha level 0.05. If this comparison is not statistically significant, then the comparison 
of key secondary efficacy endpoints will be considered 
nominal, descriptive, and exploratory. 
Additional Secondary Efficacy Analyses: 
For the Renal Evaluable Population, renal best response will be 
analyzed in the same manner described for the primary efficacy 
endpoint. For the Peripheral Neuropathy Evaluable Population, 
the change from baseline in NIS -LL total score will be analyzed 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 17 of 111 in the same manner described for the SF -36v2. For the Hepatic 
Evaluable Population, hepatic best response will be analyzed in 
the same manner described for the primary efficacy endpoint. 
Safety A nalyses:  
Safety will be assessed through summaries of AEs, changes in 
laboratory test results, and changes in vital signs. In addition, 
all SAEs, including deaths, will be listed and summarized separately.  
Sample Size Justi fication  
 For the primary endpoint, the assumed true rates for NEOD001 vs placebo are 50% and 22.5%, respectively. Based on a two -
sample comparison of proportions at the alpha=0.05 level of 
significance, a total sample size of  100 subject s (50 in the 
NEOD0 01 arm, 50 in the placebo arm) will provide >80% 
power based on a two- sided CMH  test.  Based on the actual 
enrolled sample size (N~130), the final power is 91%. 
Sponsor  Prothena Therapeutics Limited  
 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 18 of 111 Table 1 Schedule of Assessments 
  Screening1 Treatment  Termination  
 Assessment or Procedure  Days -28 
through -1 Month 1  
Day 1  Months 2 through 12  
Day 1 (±5  days )2 EOS/ETD3  Written Informed Consent  X    
Eligibility Review  X    Clinical  Medical History4 X    
Historical NT -proBNP/BNP5 Levels  X    
Prior/Concom itant Medications/Therapy  X X X X 
Adverse Event Assessment6 X X X X 
Confirmation of AL Amyloidosi s7 X    
Physical Exam8 X X X X 
Vital Sign s9 X X X X 
ECOG PS/NYHA Clas s9 X X X X 
NIS-LL & VASP I11 X X X (Months 3, 6, 9, 12)  X 
SF-36v212 X  X (Months 3, 6, 9, 12)  X 
KCCQ13 X  X (Months 3, 6, 9, 12)  X 
6MWT14,15 X, X16  X (Months 3, 6, 9, 12 )17 X 
Echocardiogram18 X  X (Month 12)  X 
ECG (12 -lead triplicate)  X X19 X (Months 3, 6, 9, 12) 19 X Laborator y24 Hematology & Chemistry (including amylase 
and creatine kinase)20 X X X X 
Coagulation21 X  X X 
Inflammatory Biomarker s22,23  X X (Month 3 )23 X 
Troponin T  X  X X 
NT-proBNP14  X X X X 
Pregnancy (WOCBP )25 X  X X X 
Serum Free Light Chain  X  X (Months 3, 6, 9, 12)  X 
Serum IFE & PEP26 X  X (Months 3, 6, 9, 12)  X 
Urinalysis – Dipstick27 X X X (Months 3, 6, 9, 12)  X 
Urinalysis - Quantitative/Renal Biomarker s28 X  X (Months 3, 6, 9, 12)   
24-hour Urine Collection:      
Urine IFE & PEP26 X  X (Months 3, 6, 9, 12)  X 
Urine Protein Excretion  X  X (Months 3, 6, 9, 12)  X Other  Serum NEOD001 Sampl e23,29  X X (Months 3, 6, 9, 12 )23 X 
Anti-NEOD001 Serum Sampl e23,30   X X (Months 3, 6, 9, 12 )23 X 
Archive Sample31 X  X (Months 6, 12)   
 Randomization   X   
 Study Drug Infusion32  X X  
 Vital Status Phone Call     X33 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 19 of 111 BNP  = B- type natriuretic peptide; ECG  = electrocardiogram; ECOG PS  = Eastern Cooperative Oncology Group 
performance status; EOI  = end of infusi on; EOS  = End of Study; ETD  = Early Treatment Discontinuation; 
IFE = immunofixation electrophoresis; KCCQ  = Kansas City Cardiomyopathy Questionnaire;  
NIS-LL = neuropathy impairment score – lower limbs; NT-proBNP  = N- terminal pro -brain  natriuretic peptide; 
NYHA  = New York Heart Association; PEP  = protein electrophoresis; PK  = pharmacokinetic; 
6MWT  = 6-m inute walk test; SF -36v2  = Short  Form -36v2® Health Survey; VASP I  = visual analog scale – pain 
intensity; WOCBP  = women of childbearing potential.  
1. Individual t est results that do not meet eligibility requirements may be repeated, with the exception  of 6MWT; 
full rescreening is allowed once per subject.  
2. Study visits will occur every 28 days based on scheduling from Month 1- Day 1 . A ±5-day window is allowed 
for vi sits starting after Month 1.  The predose assessments for each visit may be performed within the 3 days 
before the visit unless otherwise specified.  
3. Conduct the EOS Visit 30 (±5) days after last administration of study drug. Subjects who discontinue study 
drug before the end of the study should have an ETD Visit 30 (±5) days after their final administration of study 
drug, and if willing, have assessments monthly  per Appendix 13 (see also Section 4.3). Every effort should be 
made for the subject to return to the clinic and complete the Month 12 -Day 1 Visit on schedule. The 
assessments shown for EOS/ETD should also  be conducted for any unscheduled visit (i.e., a visit not specified 
by the protocol) as clinically indicated or if deemed  necessary.  
4. Obtain comprehensive cardiac, hematologic, and oncologic medical history; additio nally, for all other 
conditions  obtain relevant medical history for the past 5  years (including all major hospitalizations and 
surgeries), as well as the subject’s current medical status.  
5. If available, record results of at least 2 prior NT -proBNP or 2 BNP measures from within the previous 6 
months; N T-proBNP is preferred, but BNP may be used if it is the institution’s historical standard.  
6. Adverse events will be collected from the time that the informed consent form is signed through 30 days after 
the last dose of study drug or last study visit , whichever is later.  
7. Results from mass spectrometry tissue typing, immunoe lectron microscopy, gene sequencing, and/or 99mTc 
scintigraphy must be obtained prior to randomization to assess eligibility for subjects identified in Inclusion Criterion #3. 
8. Screening and EOS/ETD:  conduct a complete p hysical examination , including height  (Screening only), 
weight, and examination of the following:  general appearance; head, ears, eyes, nose, and throat; neck; skin; cardiovascular system; respiratory system; gastrointestinal system; and nervous system. All other visits: 
conduct a  directed p hysical exam ination , including weight,  and the components of the exam will be as clinically 
indicated. All visits:  assess macroglossia, submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen 
size (palpable +/-), ascites (+/ -), and edema (which should be quantified on a scale of 0 -4). 
9. Vital signs include heart rate (HR), respiratory rate (RR), blood pressure (BP), and body temperature; assess 
after subject has been at rest ≥5 minutes; within a visit, assess in the same position for all time points. Month 1: 
Within 30 minutes before dosing , 60 (±10) minutes after the start of the infusion , at EOI (+5  minutes), 30 (±5) 
minutes after EOI, and 60  (±10) minutes after EOI. All Other Months: Within 30 minutes before dosing, at 
EOI (+5  minutes), and 60  (±10) minutes after EOI. 
10. See Appendix 7 (ECOG) and  Appendix 8 (NYHA).  
11. See Appendix 5 (NIS-LL; for all subjects with peripheral neuropathy  at Screening ) and  Appendix 6  (VASPI ; for 
subjects
 with painful peripheral neuropathy  at Screening ). 
12. See Appendix 9; SF-36v2 should  be administered before perform ing any other study assessments  on the  same 
calendar day it is admini stered . 
13. See Appendix 10;  administer KCCQ after the SF -36v2, but before  conducting any other assessments  on the  
same calendar  day it is administered . 
14. NT-proBNP should  be drawn before conducting 6MWT  if being performed on the sa me calendar day .  
15. Collect blood pressure and heart rate pre- and post -6MWT administration. Subject should plan to be able to 
return to the same clinical site for each 6MWT from first Screening through Month 12.  
16. Two pretreatment 6MWTs are required before th e first administration of study drug, with a minimum of 4 days 
in between the two tests. The first Screening 6MWT is required to be performed between Days -28 and - 5, at 
least 4 days prior to the second Screening 6MWT, which should be performed within 2 days prior to Month 1-Day 1 (i.e., on Day -2 or Day - 1). 
Study Drug: NEOD001 CONFIDENTIAL 
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 20 of 111 17. The postbaseline 6MWT s may be administered on the same calendar day that study drug is administered  (i.e., 
Months 3, 6,  9, 12) as long as the NT -proBNP  sample  is drawn before conducting the 6MWT and th e 6MWT is 
completed before  initiation of the  study drug infusion. 
18. Perform  echocardiogram  locally; Screening:  If an echocardiogram  was conducted within 90 days prior to 
Screening Day -28, it does not need to be repeated during Screening and the previous res ult may be used  for 
eligibility ; however, to be eligible for the additional cardiac imaging analysis , the subject  must have had a 
4-chamber view, 2 -dimensional echocardiogram with Doppler.  Month 12:  may be conducted within 10 days 
before Day  1; EOS/ETD: repeat if not performed within 60 days prior to visit.   
19. Months 1 , 3, 6, 9, 12:  perform ECGs  centrally  within 30 minutes before dosing and within 15 minutes after 
EOI.  
20. Hematology  and chemistry per Appendix 11.  
21. Collect PT/INR and  PTT at each time point. At Screening, EOS/ETD, and as clinically indicated, col lect 
citrated plasma samples for freezing and  for potential analysis of coagulation indices at a later date; these 
analyses may include, but may not be limited to, the indices listed in  Appendix 12. 
22. Inflammatory bio markers per Appendix 11.  
23. Collect additional samples as clinically indicated, such as when significant toxicity occurs  per Section 5.4.2 . 
24. All laboratory tests to be done centrally, unless otherwise noted.  Please refer to Laboratory Manual for details.  
25. Pregnancy tests for WOCBP as follows: Screening:  serum test (central) within 28 days before Month  1-Day 1; 
Month 1: serum  test (local) within 24 hours before Month 1 -Day 1 ; Months 2 -12: serum  test (local) 
preinfusion; EOS/ETD:  serum test (central) ; 90 (±5) days after the last study drug administration : serum 
test (local) . 
26. The serum and urine PEP must be conducted before  the NEOD001 infusion, if being performed on the same 
calendar day . 
27. Per Appendix 11.  
28. Per Appendix 11. It is important that the sample be taken before exercising and at approximately the same time 
for each collection; therefore, the first morning void  is recommended . Urine samples will be collected and 
frozen for potential analysis at a later date.   
29. NEOD001  serum  samples  (for population PK analysis) : collect  within 2 hours before i nfusion  and within  
4 hours after EOI. 
30. Anti-NEOD001  serum sample s: collect pre infusion. 
31. Archive samples (only subjects who consented to the collection and archiving of their samples for future 
correlative testing): collect preinfusion . 
32. A minimum of 21 days between doses is r equired. Subjects should be closely monitored for 90 (±10) minutes 
following completion of the study drug infusion.  The Investigator may increase this standard monitoring time if 
deemed appropriate or per local standards. In the event of any clinical concerns or suspicious signs or symptoms 
after the infusion, the subject will remain under observation for as long as the Investigator deems it appropriate.  
Beginning with the third infusion, the Investigator may decrease the monitoring time to no less than 60 minutes, 
if no infusion- related reactions were observed in the previous infusions  and allowed per  the IRB/ IEC. 
33. For randomized subjects who received at least 1 dose of study drug, conduct v ital status  telephone call 
approximately 3 months  after last v isit and approximately every 3 months thereafter or until subject enrolls in a 
separate open -label study, death, or for up to 5 years . 
Study Drug: NEOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 21 of 111 Figure  1 NEOD001 -201 Study Design 
 
Screening
 Treatment (N~130)
 Termination
Days -28 to -1 Months 1 through 12
Day 1 (±5 daysd)30 (±5) Days 
After Last DosePopulation:
Previously
treated AL 
amyloidosis
Response to 
first-line PCD 
therapy,
6-month 
treatment -free 
intervala
Cardiac
involvement
ICF & 
Screening 
Assessments
24 mg/kgb IV NEOD001 every 28 days
EOS/ETD 
Visit
CR = complete response; EOS/ETD = End of Study/Early Treatment Discontinuation; ICF = informed consent form; IV = intravenous ; M12 = Month 12; NT -proBNP = N -terminal pro B -type natriuretic peptide; NIS -LL = 
Neuropathy Impairment Score -Lower Limbs; PCD = plasma cell dyscrasia; PCS = Physical Component Summary; PR = partial response; SF -36 = Short Form -36; 6MWT = 6 minute walk test; VGPR = very good partial response.
a 6 months chemotherapy or 12 months stem cell transplant treatment -free. 
b Maximum dose not to exceed 2500 mg.
c Eligible subjects will receive active treatment and may receive concurrent chemotherapy.
d ±5-day window applicable to Months 2 -12.
e Renal -evaluable subjects, peripheral neuropathy -evaluable subjects, and hepatic -evaluable subjects, respectively.
IV Placebo every 28 daysRandomization 1:1
Randomization Stratification:
• Hematologic response; i.e., CR+VGPR vs PR to first -line therapy
• NT-proBNP <1800 pg/mL vs ≥1800 pg/mL
Primary Endpoint: 
• NT-proBNP best response from baseline through 12 months of treatment
Key Secondary Endpoints:
• SF-36 PCS change from baseline to 12 months of treatment
• 6MWT distance change from baseline to 12 months of treatment
• NT-proBNP slope over 12 months of treatment
Secondary Endpoints in Efficacy Subset Populationse:
• Renal best response from baseline through 12 months of treatment
• NIS-LL Total Score change from baseline to 12 months of treatment
• Hepatic best response from baseline through 12 months of treatment
Open -label 
Extension 
Studyc  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 22 of 111 GLOSSARY OF TERMS  
Abbreviation/Acronym Definition  
6MWT 6-minute  walk test 
99mTc Radioisotope of technetium 
AA Amyloid A 
ADA(s)  Anti-drug antibody(ies)  
ADL  Activities of daily living  
AE(s)  Adverse event(s)  
AEF  Amyloid -enhancing factor  
ALP  Alkaline phosphatase 
AL Amyloid light chain  
ALT  Alanine aminotransferase 
ANC  Absolute neutrophil count 
ASCT  Autologous stem cell transplant 
A-SAA  Acute phase serum amyloid A  
AST  Aspartate aminotransferase 
AV Atrioventricular  
BNP  B-type natriuretic peptide  
BP Blood pressure 
BSA  Bovine serum albumin 
BUN  Blood urea nitrogen  
CKD- EPI Chronic Kidney Disease Epidemiology Collaboration 
CMH  Cochran -Mantel -Haenszel  
CR Complete response 
CRP  C-reactive protein  
CT Computerized tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
D Aspartic acid  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 23 of 111 Abbreviation/Acronym Definition  
dFLC  Difference b etween involved and uninvolved free light chains 
E Glutamic acid  
ECG  Electrocardiogram  
ECL  Electrochemiluminescent  
ECOG Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
eGFR  Estimated glomerular filtration rate  
EOI End of infusion 
EOS  End of Study 
ETD  Early Treatment Discontinuation  
FDA  Food and Drug Administration 
FLC Free light chain  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus 
HR Heart rate  
ICF Informed consent form 
ICH Inter national Conference on Harmonisation 
IEC Institutional Ethics Committee  
IFE Immunofixation electrophoresis 
Ig Immunoglobulin 
IgG1  Immunoglobulin G1 
IL-6 Interleukin-6 
IMWG  International Myeloma Working Group 
INR International normalized ratio  
IRB Institutional Review Board  
ITT Intent- to-treat 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 24 of 111 Abbreviation/Acronym Definition  
IV Intravenous or intravenously 
IVSd  Intraventricular septal at diastole  
IWRS  Interactive Web Response System  
KCCQ  Kansas City Cardiomyopathy Questionnaire 
LDH  Lactate dehydrogenase  
LPWd  Left posterior w all at diastole  
LVEF  Left ventricular ejection fraction  
MCS  Mental Component Summary  
MMRM  Mixed models for repeated measurements  
NGAL  Neutrophil gelatinase- associated lipocalin  
NIS-LL Neuropathy Impairment Score– Lower Limbs  
NOAEL  No-observable- advers e-effect -level  
NR No response 
NT-proBNP  N-terminal pro -brain natriuretic peptide  
NYHA  New York Heart Association  
PCD  Plasma cell dyscrasia  
PCS Physical Component Summary  
PEP Protein electrophoresis 
PK Pharmacokinetic(s)  
PR Partial response  
PS Performance status  
PT Prothrombin time  
PTT Partial thromboplastin time  
RBP  Retinol-binding protein 
RR Respiratory rate  
SAA Serum amyloid A 
SAE  Serious adverse event  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 25 of 111 Abbreviation/Acronym Definition  
SC Subcutaneous(ly) 
SF-36v2 Short Form-36v2® Health Survey 
SMC  Safety Monitoring Comm ittee 
TEAE(s)  Treatment -emergent adverse event(s)  
TRIAD  Transgenic Rapidly Inducible Amyloid Disease 
ULN  Upper limit of normal 
US(A)  United States (of America)  
USP United States  Pharmacopeial Convention 
VASPI  Visual Analog Scale – Pain Intensity  
VGPR  Very good partial response 
WFI Water for injection  
WOCBP  Women of childbearing potential 
WT Wild -type 
 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 26 of 111 1 INTRODUCTION 
1.1 Light Chain (AL)  Amyloidosis 
Systemic amyloidoses are a complex group of diseases caused by tissue deposition of misfolded 
proteins that result in progressive organ damage. The most common type, light chain (AL) amyloidosis or primary systemic amyloidosis, involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains by plasma cells results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs of individuals with AL amyloidosis. Clinical features of AL amylo idosis include a constellation of 
symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement, neuropathy and macroglossia. The mechanisms by which amyloidogenic immunoglobulin light chains result in organ dysfunction are not well characterized, however, it is hypothesized that both amyloid deposits and prefibrillar aggregates may contribute to cytotoxic effects on organs observed in patients with AL amyloidosis.  
AL amyloidosis is a rare disorder. The over all incidence of AL amyloidosis is estimated to be 
8.9/million persons/year (CI: 5.1, 12.8) (Kyle  et al,  1992; Pinney et al,  2013). NEOD001 was 
designated as an Orphan Medicinal Product in the European Union on 08 February 2013 for the 
treatment of AL amyloidosis and in the US on 17 February  2012 for the treatment of AA 
amyloidosis and AL amyloidosis.  
Approximately three -fourths of AL amyloidosis patients present with 1 or 2 major organ systems 
involved (e.g., cardiac, renal, gastrointestinal tract, hepatic, autonomic nervous system, 
peripheral nervous system, soft tissues) while a quarter  of patients present with >2  systems 
involved ( Palladini et al, 2005; Gertz et al, 2010). AL amyloidosis is most commonly associated 
with cardiac and/or renal dysfunction, with overt restrictive cardiomyopathy observed in approximately 50% of all cases, and subclinical cardiac involvement detected in almost every case at autopsy or on endomyocardial biopsy ( Falk and Dubrey, 2010 ).  
AL amyloidosis has two important disease components. The first component is the plasma cell dyscrasia (PCD), which results in the overproduction of immunoglobulin light chain, and the second component is the impact of the soluble and insoluble amyloid on organ structure and function, leading to the clinical manifestations of the disease . While there are no approved 
treatments for AL amyloidosis, the c urrent standard of care for these patients is aimed at 
reducing or eliminating the bone marrow disorder, the PCD . The most aggressive treatment 
options include autologous stem cell transplant (ASCT) and high-dose chemotherapy for those patients who can tol erate it . Other treatment regimens include combinations of drugs often used 
to treat hematological malignancies including melphalan, prednisone, dexamethasone, and proteasome inhibitors (e.g., bortezomib), in an attempt to reduce light chain production. Th ere 
are no currently approved treatments for AL amyloidosis, and none that directly target potentially toxic forms of the amyloidogenic proteins. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 27 of 111 1.2 Study Rationale 
The pathobiology of AL amyloidosis results from PCD, which causes the overproduction of 
immuno globulin light chain, and soluble aggregates and insoluble amyloid that have a profound 
impact on organ structure and function, leading to the clinical manifestations of the disease. Unlike other hematologic disorders such as multiple myeloma, the morbidit y and mortality of 
AL amyloidosis is related to organ dysfunction rather than the PCD. In all patients with AL 
amyloidosis, disease outcome is highly dependent on the severity of organ involvement, especially cardiac involvement; and prognosis can be defin ed by N–terminal pro -brain  natriuretic 
peptide (NT- proBNP). For this study, NT-proBNP was chosen as the primary endpoint because 
it is a validated  cardiac functional biomarker of injury and dysfunction and decreasing NT -
proBNP levels predict lower mortalit y rates (Comenzo et al, 2012) . NT-proBNP can also be used 
for early assessment of cardiac response, allowing treatment modification  (Palladini et al, 2014).  
In the completed Phase 1/2 study of NEOD001 in subjects with AL amyloidosis, monthly 
infusions of NEOD001 resulted in clinically meaningful reductions in NT-proBNP  (Gertz et al, 2016). 
Currently , there are no approved treatments for AL amyloidosis and no exis ting treatments that 
directly neutralize the toxic soluble aggregates or remove the organ deposited misfolded amyloid that are thought to cause organ dysfunction ( Falk and Dubrey, 2010 ). Current treatment 
approaches are aimed at  reducing or eliminating  the PCD, which produces the toxic amyloid 
(i.e., eliminating or reducing the plasma cells responsible for producing light chains, thereby reducing or halting production of the toxic protein). These include high- dose chemotherapy an d 
ASCT for patients who can tolerate those treatments. Indeed, the incidence of treatment- related 
mortality following ASCT is high (although variable and treatment center dependent) with the greatest mortality in patients with cardiac involvement ( Falk and Dubrey, 2010).  Falk and 
colleagues noted that although complete hematologic responses could be achieved in approximately 40% of treated patients ( Falk and Dubrey, 2010), the rate of any organ functi on 
improvement or stabilization (“organ response”) after achieving hematologic response from ASCT or chemotherapy regimens is highly variable ( Cibeira et al, 2011; Cohen et al, 2007; 
Michael et al, 2010 ). This is significant in as much as hematologic response in the absence of 
organ benefit provides limited if any, clinical benefit to patients with AL amyloidosis  (Kaufman  et al,  2015) an d underscores the fact that the major determinant of morbidity and 
mortality is end organ damage.  
NEOD001 is currently being studied in a double-blind, randomized, placebo -controlled Phase 3 
study (The VITAL Amyloidosis Study; Study NEOD001-CL002) in newly diagnosed patients 
with AL amyloidosis disease receiving chemotherapy to  treat  the underlying P CD. In addition, 
Study NEOD001 -OLE001, a Phase 2  open-label extension study for subjects who completed 
9 months of treatment in the Phase 1/2 Study NEOD001-001, allows subjects to receive NEOD001 and concomitant chemotherapy for treatment of their underlying PCD. Study NEOD001 -201 is designed to evaluate the efficacy and safety of NEOD001 as a single agent in 
AL amyloidosis subjects whose underlying PCD is stabl e but who still exhibit significant organ 
impairment.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 28 of 111 1.3 Background on NEOD001  
Prothena Therapeutics Limited (Prothena) is developing NEOD001, a humanized 
immunoglobulin G1 (IgG1), kappa version of 2A4, the parent murine monoclonal antibody, which is directe d against a cryptic epitope on amyloid fibrils. NEOD001 specifically targets 
misfolded light chain aggregates and amyloid deposits. In the course of specificity 
characterization of NEOD001, the antibody was found to also react with high affinity and in a conformation-dependent manner with the misfolded light chain found in soluble aggregates and deposited light chain  amyloid fibrils, however not with immunoglobulin (Ig) or free non-amyloid 
light chain  in circulation.  NEOD001, administered by intravenous ( IV) infusion, is proposed for 
use to target the misfolded light chain protein in subjects with AL amyloidosis. See the current NEOD001 Investigator’s Brochure for detailed nonclinical and clinical information.  
The proposed mechanism of action for NEOD001 is thought to be two- pronged ( Figure 2) . First, 
is the direct interaction of NEOD001 with soluble aggregates resulting in the neutralization of 
the soluble, toxic aggregated moieties. The second is clearing the insol uble toxic amyloid 
deposited in organs/tissues. Here, it is believed that NEOD001 attaches to the amyloid deposits and the intact Fc portion of NEOD001 signals monocytes/macrophages to the area; and via phagocytosis, clearance of the insoluble, toxic deposits occurs (e.g., opsonization of the deposited amyloid). It is believed that both mechanisms may contribute to potential clinical 
benefit.  
Figure  2 Proposed Mechanism of Action for NEOD001  
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 29 of 111 Because NEOD001 and 2A4 (the parent murine monoclonal antibody for NEOD001) recognize a 
conserved epitope in both the AL and serum amyloid A (AA) proteins, nonclinical efficacy was evaluated in mouse models of both systemic serum AA amyloidosis (H2/hIL- 6 Transgenic 
Rapidly Inducible Amyloid Dis ease [TRIAD] mouse model) and AL (am yloidoma xenograft 
model) using 2A4. In the AL xenograft model, treatment with ~5 mg/kg of 2A4 subcutaneously (SC), 3 times a week resulted in a statistically significant reduction in the size of the amyloidomas that wer e formed (by weight and volume). Efficacy studies in the TRIAD mouse 
model at the same dose demonstrated improvements in survival and, in some experiments, reductions in amyloid load. A single experiment using high doses of 2A4 (40 mg/kg) at either 1 week after disease induction vs 3 weeks after disease induction (when organ amyloid burden is well established) generated conflicting results; with increased organ amyloid burden in the early treatment arm, but decreased organ amyloid burden in the late treatment arm. At this time, no explanation for these differences has been found.  
Imaging, autoradiography, and biodistribution studies demonstrated specific binding of 
NEOD001 and 2A4 to their amyloid target in the TRIAD and AL xenograft models. No evidence has been found that would indicate relevant off-target binding of NEOD001 (e.g., to endogenous 
parent proteins of the amyloid), consistent with the results of the human tissue cross- reactivity 
study with NEOD001 discussed below. 
1.3.1 Nonclinical Safety  
Nonclinical  safety was evaluated in the cynomolgus monkey, the TRIAD mouse model, and an 
in vitro  study examining binding to human tissue. 
Cynomolgus monkey: Important amino acid contributions to the epitope in AL amyloidosis are glutamic acid (E) and aspartic acid ( D) at positions 81 and 82, respectively, on IgG light chain 
and these are conserved in this species; i.e., the incidence of E and D at these positions is >90% in both cynomolgus monkey and human. Though the aspartic acid is buried in the normally folded light chain, if physiologic conditions arise that result in the revealing of this epitope, or if there is binding to similar epitopes on other proteins, then the consequence would be evaluable in this species.  
In a 28-day, weekly IV dose study of NEOD001 in cynomolgus monkeys with a 28- day 
dose-free period for control and high dose animals, treatment was well- tolerated at all dose levels 
(10, 50, and 100 mg/kg/week) . There were no NEOD001 -related changes in any of the study 
parameters evaluated and thus the no-observable -adverse- effect -level (NOAEL) for NEOD001 
in this species was 100 mg/kg . Serum levels of NEOD001 were maintained throughout the 
treatment period . The data suggest a low risk of off- target toxicity.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 30 of 111 H2/hIL -6 TRIAD mice:   The TRIAD mouse model of AA amyloidosis has limitations relative 
to safety assessment for AL amyloidosis; e.g., 1) this transgenic model overexpresses human 
interleukin -6 (IL -6), creating a proinflammatory baseline state that is important for disease 
progression but can confound safety evaluation, 2) the disease state is also promoted by injection with an amyloid extract, called amyloid -enhancing factor (AEF), intended to seed tissue with 
amyloid, and 3) it involves an amyloid protein (AA) that is different than the one targeted in this population (AL), despite the fact that 2A4 recognizes both proteins. However, this model contributes to the safety assessment of NEOD001 as it is the only nonclinical model available that offers the ability to assess the potential hazards of antibo dy binding to amyloid embedded in 
various vital organs, primarily liver, spleen, and kidney. The murine homologue of NEOD001, 2A4, maintains full effector function and was used in these studies. 
Two TRIAD mouse studies were used in the nonclinical safety a ssessment: a 22 -day toxicity 
study by the IV route of administration and a 28-day toxicity study by IV and SC routes of 
administration . In addition, a 22- day special immunogenicity/toxicity study in H2/hIL -6 mice 
(no AEF) was conducted to compare 2A4 against the immunogenic potential of an unrelated protein, bovine serum albumin (BSA). These are detailed in the Investigator’s Brochure and the key points are summarized below. 
As intended for this disease model, the TRIAD mouse has background pathology. Appropriate 
controls demonstrated the effect of the IL -6 transgene (plasmacytosis in spleen, thrombus 
formation in mesenteric vessels) and the effect of the IL -6 transgene with AEF added (amyloid 
deposition in kidney, liver, spleen, and other tissues; inflammat ory infiltrates in the heart; and 
renal pathology, including tubular degenerative changes and papillary necrosis). Importantly, no additional pathology was observed that was attributable to 2A4 treatment at the doses studied, 4 and 40 mg/kg/week.  
In both toxicity studies, mortality was observed acutely following the third weekly dose 
(Study  Day  15) when 2A4 was administered by bolus IV administration. No pathology was 
present to indicate mechanism of the cause of death . The timing of the adverse reaction being 
within minutes to hours of the third weekly dose, and the presence of anti-drug antibodies (ADAs), suggest that the effect is an ADA -mediated phenomenon in this model. In animals that 
survived, there were no adverse effects described surrounding deposited amyloid, or in other tissues. Anti- drug antibody  reactions in animal species are not predictive of human responses 
and, therefore , these effects are not considered to contribute to human risk assessment  
(Bugelski and Tre acy, 2004; Pimm and Smith, 1992). Additionally, w hile it is possible that 
ADAs might develop, it is not known whether or not this would be associated with any clinical significance.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 31 of 111 A special immunogenicity/toxicity study was conducted to explore whether the mortality 
observed following IV dosing of 2A4 in the TRIAD mouse can be observed with an unrelated, but immunogenic protein. Nontransgenic/wild -type (WT) mice and H2/hIL -6 transgenic mice 
(no AEF administered) were treated once weekly by IV administration with 2A4 at 4 mg/kg . The 
nontransgenic mice showed no systemic effects; however, the IL-6 overproducing mice developed profound signs (decreased motor activity, hunched posture, ataxia, cold to touch) immediately after dosing on Days 15 and 22, replicating what was observed in the TRIAD mouse safety studies above. Mortality and moribundity occurred post dosing on Day 22. Another group of H2/hIL- 6 transgenic mice was treated once weekly by IV administration with BSA at 
50 mg/ kg. A similar clinical course occurred although signs began one week earlier; i.e. after 
dosing on Day 8 (the second dose). Again, mortality was observed in some animals after dosing on Day 22. This study demonstrates the importance of elevated IL -6 in the morbidity and 
mortality observed in this model and further demonstrates that the mortality is not unique to 2A4 but can be seen with other proteins that are immunogenic in this mouse model. 
Human tissue cross -reactivity :  In a human tissue cross- reactivit y study of NEOD001 designed 
to examine potential off -target effects, a limited number of tissues demonstrated any binding . 
Cytoplasmic staining was observed in the heart, kidney, pancreas, pituitary, and testis. 
Cytoplasmic staining is generally not consid ered to be relevant to IV dosing as these sites are not 
accessible to the administered antibody . Rare to occasional, mild -intensity membrane staining 
was observed on ductular and tubular epithelial cells of the pancreas and testis, respectively. No pathologic changes were observed in these organs in the repeat -dose studies suggesting limited 
safety liabilities from potential binding in these tissues . Overall, these data confirm the 
prediction of a low potential for binding of NEOD001 to normal tissue. 
In su mmary, the available nonclinical data support clinical development of NEOD001 for the 
treatment of AL amyloidosis . No target organ toxicity has been described . Based on available 
models, there are limitations on the ability to assess the interaction of NEO D001 with deposited 
or soluble AL amyloid. The investigations in an AA amyloidosis model (the TRIAD mouse) 
provide some reassurance that binding of 2A4, an antibody with full effector function, does not appear to adversely react with deposited amyloid in t issue . Nevertheless, monitoring for changes 
in disease pathology, as would typically be performed in clinical development, is warranted. 
1.3.2 Clinical Experience 
Study NEOD001 -001 was a Phase 1/2 open-label, dose escalation study of the IV administration 
of sin gle-agent NEOD001 in subjects with AL amyloidosis previously treated for their plasma 
cell dyscrasia (PCD), which enrolled 27 subjects in the Escalation Phase in 7 cohorts (evaluating dose levels from 0.5 mg/kg to 24.0 mg/kg) and enrolled an additional 42 subjects in the Expansion Phase. The most frequently reported treatment- emergent adverse events (TEAEs) 
overall in Study NEOD001- 001 (occurring in ≥20% of subjects [N=69], regardless of 
relationship to NEOD001) were fatigue, nausea, upper respiratory tract infection, edema peripheral, diarrhea, and anemia. No confirmed anti -NEOD001 antibodies were detected. No 
dose- limiting toxicities (DLTs) or treatment- related serious TEAEs were reported.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 32 of 111 Efficacy data from the completed Study NEOD001 -001 were previously reported by  Gertz et al. 
(2016)  and final data are summarized herein. Cardiac response was assessed by the clinically 
relevant cardiac biomarker, NT proBNP, using Comenzo 2012 criteria ( Appendix 4). Thirty- six 
subjects were considered cardiac evaluable (i.e., Screening NT -proBNP ≥650 pg/mL). Among 
cardiac evaluable subjects, 50% (n=18) met the criteria for cardiac best response and 50% (n=18) 
met cardiac best response category of stable disease. Renal response was defined according to Palladini 2014 criteria ( Appendix 4). Thirty -six subjects were considered renal evaluable (i.e., 
Screening proteinuria ≥0.5 g/24 hours). Among renal evaluable subjects, 64% (n=23) met the criteria for renal best response and 36% (n=13) met renal best response category of stable disease. Peripheral neuropathy response was defined according to Coelho 2012 criteria (Appendix 4). Eleven subjects (all in the Peripheral  Neuropathy Expansion Cohort) were 
considered peripheral neuropathy evaluable. At Month 10, 82% (n=9) of the peripheral neuropathy evaluable subjects met the criteria for peripheral nerve response (i.e., <2 -point 
increase in Neuropathy Impairment Score– Lower Limbs [NIS -LL] score [88 -point scale] from 
Screening) and 18% (n=2) were progressors. Two of the responders had complete resolution of peripheral neuropathy at Month 10. 
Eligible subjects from Study NEOD001-001 enrolled in Study NEOD001-OLE001, an open-
label extension study to evaluate the long-term safety and tolerability of NEOD001 in subjects with AL amyloidosis. Subjects receive 24 mg/kg NEOD001 once every 28 days using the infusion duration established for the individual subject in Study NEOD001 001 or over 60 (±10) minutes. As of the data lock point, 11 subjects experienced TEAEs and no treatment- related 
TEAEs, serious TEAEs, discontinuations due to TEAEs, or deaths were reported. 
Study NEOD001 -CL002 (VITAL) is an ongoing Phase 3, multicenter, international, randomized, 
double-blind, placebo-controlled, two- arm efficacy and safety study in subjects with AL 
amyloidosis. Newly diagnosed subjects with AL amyloidosis are randomized in a 1:1 ratio to 
received either NEOD001 (24 mg/kg) plus standard of care or placebo plus standard of care, administered once every 28 days as a 1 - to 2-hour IV infusion. All subjects are premedicated 
with 25 mg diphenhydramine (or an equivalent dose of an H1 antihistamine) and 650 mg acetaminophen (or an equivalent dose of pa racetamol) within 30 to 90 minutes prior to the start 
of the infusion. As of the data lock point and including late-breaking events, 68 (52.7%) subjects experienced at least 1 serious TEAE, 2 of which had events considered related to study drug (treatment blinded), 19 (14.7%) subjects had died, none of which were considered by the Investigator to be related to study drug treatment, and 5 (3.9%) subjects had TEAEs that lead to study drug discontinuation.  
In an overabundance of caution, premedication is required in Study NEOD001- CL002 because 
subjects are also receiving standard of care chemotherapy. But, due to the limited number of 
infusion- related reactions (IRRs) reported to date, premedication will not be routinely 
administered in the ongoing Studies NEOD001-201, NEOD001-OLE001, and NEOD001-
OLE251, unless the Investigator observed an IRR with a prior infusion of study drug in an individual subject.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 33 of 111 As of 30 September 2016, 221 subjects had been dosed with a total of 1638 infusions of 
NEOD001 or placebo in the 4 completed or ongoing studies. In the completed Study NEOD001 -001, <1% of infusions administered were associated with IRRs (e.g., rash, 
hypotension). These IRRs were Common Terminology Criteria for Adverse Events (CTCAE) Grades 1 or 2, nonserious, considered possibly or probably related to study drug, and most resolved within 24 hours. In the ongoing Study NEOD001-CL002 (VITAL), <1% of infusions of study drug (treatment blinded) were associated with infusion- related TEAEs.  These TEAEs, 
experienced by  5 subjects, were Grade 1 or 2, nonserious, and most were considered related to 
study drug (treatment blinded), and 2 were ongoing at the time of the data lock point. Two events required interruption of the infusion. 
Based on the data available to date, NEOD001 has been well tolerated as single-agent therapy in 
subjects with AL amyloidosis and limited clinically significant safety signals have been identified.  
Further details can be found in the latest edition of the NEOD001 Investigator’s Brochure. 
1.4 Rationale for Study Design and Dose S election  
Since preliminary data have indicated that NEOD001 as a single agent in previously treated 
subject s appears to improve NT-proBNP ( Gertz et al, 2016) , a randomized, double-blind, 
placebo -controlled, two- arm, parallel -group design was selected to evaluate the safety and 
efficacy of NEOD001 vs placebo in subjects with AL amyloidosis. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 34 of 111 2 OBJECTIVES  
The objective of this study is to determine the efficacy and safety of NEOD001 versus placebo in 
subject s with AL amyloidosis who have persistent cardiac dysfunction. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 35 of 111 3 STUDY PLAN  
3.1 Study Design  
This is a  global, multicenter , Phase 2 b, randomized, double-blind, placebo -controlled, two -arm, 
parallel -group efficacy and safety study of NEOD001 as a single agen t administered 
intravenously in adults with AL amyloidosis who had a hematologic response ( Appendix 1)  to 
previous treatment for their amyloidosis (e.g., chemotherapy, ASCT) and have persistent cardiac 
dysfunction. 
Subject screening will occur during the 28 days prior to the first administration of study drug 
(i.e., Month 1- Day 1 Visit) . If all eligibility requirements are met, the subject will be enrolled 
and Screening assessments will be completed. Screening assessments are li sted in Table 1.  
Study visits will occur every 28 days based on scheduling from Month 1-Day 1. A ±5- day 
window is allowed for visits starting after Month 1. Subjects may receive up to 12 infusions of study drug. Subjects who discontinue study drug before the End of Study (EOS) Visit should have an Early Treatment Discontinuation (ETD) Visit 30 (±5) days after their final administration of study drug (per Section 6.2). If willing, s ubjects may continue in the study and 
have monthly assessments, through Month 12, per Appendix 13. Subjects who complete the 
study and meet the eligibility criteria will be considered for entry into a sepa rate open -label 
extension study, during which subjects will receive active treatment and may receive concurrent chemotherapy . 
3.2 Endpoints  
3.2.1 Primary  Efficacy Endpoint 
• NT-proBNP best response from baseline through 12 months of treatment  
3.2.2 Key Secondary  Efficacy E ndpoints  
• Change from baseline to 12 months of treatment in the Physical Component Summary  (PCS) 
score of the Short Form-36 Version 2 (SF-36v2) 
• Change from baseline to 12 months of treatment in the 6MWT distance (meters)  
• NT-proBNP slope over 12 months of tr eatment  
3.2.3 Addition al Secondary Efficacy Endpoints 
• Renal evaluable subjects: renal best response from baseline through 12 months of treatment  
• Peripheral neuropathy evaluable subjects: change from baseline to 12  months of treatment in 
NIS-LL total score  
• Hepatic evaluable subjects: hepatic best response from  baseline through 12 months of 
treatment  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 36 of 111 3.2.4 Exploratory Efficacy Endpoints  
• Cardiac response, as assessed by NT -proBNP  response criteria, at each visit  
• Cardiac best response, as assessed by NT -proBNP  response criteria , through 3, 6, and 9 
months of treatment 
• Change and percent change from baseline to each visit in NT -proBNP and troponin T  
• Change and percent change from baseline to each visit  in selected cardiac parameters, as 
determined by a 4 -chamber view from a 2 -dimen sional echocardiogram with Doppler, as 
follows: 
o LVEF = Left ventricular  ejection fraction  
o IVSd = Intraventricular septal at di astole  
o LPWd = Left posterior wall at dia stole  
• Change and percent change from baseline to each visit (except the key se condary endpoint) 
in the 6MWT distance (meters)  
• Change and percent change from baseline to each visit in SF -36v2 PCS score (except the key 
secondary endpoint), Mental Component Summary  (MCS) score, and the 8 subscales  
• Change and percent change from baseli ne to each visit in the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) subscores and overall summary score  
• Renal Evaluable Subjects :  
o Renal response at each visit  
o Renal best response through 3, 6, and 9 months of treatment 
o Change and percent change from baseline to each visit in renal biomarkers (urine 
albumin/creatinine ratio, urinary neutrophil gelatinase- associated lipocalin [NGAL], and 
urinary retinol-binding protein [RBP]) 
o Change and percent change from baseline to each visit  in creatinine, proteinuria, and 
eGFR  
o Time to eGFR ≤15 mL/min/1.73 m2 (Chronic Kidney Stage 5) 
o Shifts from baseline in Chronic Kidney Stage 
o Time to doubling of creatinine  
• Peripheral Neuropathy Evaluable Subjects:  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 37 of 111 o Change and percent change from baseline to each visit in the NIS- LL total score  (except 
the additional secondary endpoint) 
o Peripheral neuropathy response at each visit  
o Peripheral neuropathy best response through 3, 6, 9, and 12 months of treatment  
o Change and percent change from baseline to each visit in the 3 NIS-LL component 
scores (sensory function, reflexes, muscle strength)  
o For peripheral neuropathy evaluable subjects with painful peripheral neuropathy, 
defined as a baseline VASPI score >0,  change and percent change from baseline to each 
visit in the VASPI score 
• Hepatic E valuable Subjects: 
o Hepatic response at each visit  
o Hepatic best response through 3, 6, and 9 months of treatment  
o Change and percent change from baseline to each visit  in ALP  
• Time to a ll-cause mortality (overall survival) 
• Progression- free survival  
• Duration of response 
• Time to derived organ progression for each organ (cardiac/NT-proBNP, renal, peripheral 
neuropathy, hepatic) separately and to any organ progression 
• Time to first organ response for each organ (cardiac/NT-proBNP, renal, peripheral neuropathy, hepatic ) separately and to any organ response  
• Frequency of cardiac hospitalizations over the course of the study 
• ECOG Performance Status, NYHA Class, Mayo Clinic Stage, and Renal Stage at each visit including any changes from baseline 
• Change and percent change fr om baseline to each visit in serum free light chains (FLCs), 
serum and 24-hour urine PEP, and serum and urine IFE 
• Hematologic response at each visit  
• Hematologic best response through 3, 6, 9, and 12 months of treatment   
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 38 of 111 • Disease-related symptoms (including macroglossia, submandibular nodes/fullness, 
adenopathy, ecchymoses, edema, ascites, and liver/spleen size)  at each visit and changes 
from baseline 
3.2.5 Safety Endpoints  
Safety and tolerability of NEOD001 as assessed by vital signs, 12-lead ECGs, routine labora tory 
assessments, AEs, and immunogenicity by measurement of anti-NEOD001 antibodies. 
3.3 Number of Sites and Subjects  
This is a global, multicenter  study in approximately 35 centers . Up to 130 subjects will be 
enrolled and randomized (1:1) to NEOD001 or placeb o. 
3.4 Randomization and Blinding  
3.4.1 Randomization 
A subject number will be assigned via a web -based registration for each subject who has signed 
an informed consent form (ICF) . If a subject has completed all Screening requirements and 
meets all of the eligibility criteria, a Subject Registration Form will be submitted for eligibility 
review and approval. If approved, randomization will be implemented through an internet connection to an Interactive Web Response System ( IWRS ) utilizing results from Screening 
asses sments . Up to 130 subjects will be randomized in a 1:1 ratio into one of two arms, 
NEOD001 24 mg/kg or placebo. The rand omization will be stratified by two  factors:  
• Hematologic response; that is, c omplete response/very good partial response (CR/VGPR) vs 
partial response (PR) to first -line therapy  
• NT-proBNP <1800 pg/mL vs ≥1800 pg/mL  
Upon successful randomization, the Unblinded Pharmacist or their designee (henceforth collectively referred to as the Unblinded Pharmacy Staff ) will be provided with the treatment 
assignment . Numbers assigned to subjects who do not receive study drug will not be re- used. 
Refer to the Study Manual for additional details.  
3.4.2 Emergency Unblinding  
The Investigator has the ability to break the blind for a specific subject in the event of an immediate medical emergency, wherein  knowledge of the subject’s treatment (NEOD001 or 
placebo) must be known in order to provide adequate medical treatment. In these situations, the breaking of the blind must be reported to the Sponsor or its designee within 24 hours. The procedure for the unblinding of a specific subject using the IWRS  is provided in the Study 
Manual.  
Any other requests to reveal a subject’s treatment must be requested of, and approved in writing  
by the Sponsor or its designee. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 39 of 111 In addition, in the event of any safety concern, the Safety Monitoring Committee ( SMC ) will 
have the option to unblind the treatment of any subject. In this situation, only the SMC will have  
access to the unblinded data. 
3.5 Safety Monitoring Committee 
An independent Safety Monitoring Committee (SMC), consis ting of at least 2 clinicians and a 
biostatistician not directly involved with the conduct of the trial, will meet to review specified 
blinded subject data during the conduct of the study. The purpose of these independent data reviews is to assess the tota lity of the safety data and provide a recommendation to the Sponsor 
for continuation of dosing or protocol modifications. Details will be provided in the SMC Charter.  
3.6 Estimated Study Duration 
Each subject’s study duration may be up to 14 months, consisting of a Screening Phase (1 month), Treatment Phase ( 12 months), and the EOS  Visit 30 (±5) days after the last dose. 
3.7 Definition of E nd of S tudy  
The study will end when the last subject completes 12 months of study treatment and  the 30- day 
safety follow -up period (i.e., EOS Visit) . Subjects who complete the study and meet the 
eligibility criteria will be considered for entry into a separate open -label extension study, during 
which subjects will receive active treatment and  may receive concurrent chemotherapy.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 40 of 111 4 SELECTION, DISCONTINUATION, AND WITHDRAWAL OF SUBJECT S 
4.1 Inclusion Criteria  
Subjects must meet all  of the following criteria:  
1. Age ≥18 years  
2. Confirmed diagnosis of systemic AL amyloidosis by the following:  
o Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of 
green birefringent material in Congo red -stained tissue specimens OR  characteristic 
electron microscopy appearance  
AND  
o Confirmatory electron microscopy OR  immunohistochemistry OR  mass spectrometry  of 
AL amyloidosis  
3. If the subject meets any  of the following criteria, confirm diagnosis of AL amyloidosis by 
mass spectrometry or immunoelectron microscopy of amyloid material in  tissue biopsy: 
o Is black or African American  
o Is over 75 years of age (at time of diagnosis)  with concurrent monoclonal gammopathy 
o Has a history of familial amyloidosis and has concurrent monoclonal gammopathy 
OR 
o  If the subject meets any of the above 3 conditions and has echocardiographic evidence of 
amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (
99mTc-DPD;  Rapezzi et al, 2011), 
hydroxymethylenediphosphonate (99mTc-HMDP; Galat et al, 2015 ), or pyrophosphate 
(99mTc-PYP; Bokhari et al,  2013) scintigraphy  
4. Cardiac involvement as defined by BOTH of the following: 
o  Past documented or presently noted clinical signs and symptoms supportive of a 
diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure  
o  Either an endomyocardial biopsy demonstrating AL amyloidosis OR an echocardiogram 
demonstrating a mean l eft ventricular wall thickness at  diastole >12 mm in the absence 
of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 41 of 111 5. NT-proBNP ≥650 pg/mL and ≤ 5000 pg/mL (i.e., ≥76.7 pmol/L and ≤ 590 pmol/L)  
6. Received at least one prior systemic chemotherapeutic regimen , which may include stem cell 
transplant, for AL amyloidosis 
7. Achieved at least a partial hematologic response (per Appendix 1)  to a first -line therapy 
resulting in a stable hematologic condition not currently requiring additional active treatment 
against the PCD  component of their AL disease 
8. Adequate bone marrow reserve, hepatic and renal function, as demo nstrated by:   
o Absolute neutrophil count (ANC) ≥ 1.0 x109/L 
o Platelet count ≥ 75 × 109/L 
o Hemoglobin ≥ 9 g/dL  
o Total bilirubin ≤ 2 × upper limit of normal (ULN) 
o Aspartate aminotransferase (AST) ≤ 3 × ULN  
o Alanine aminotransferase (ALT) ≤ 3 × ULN  
o  Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and 
isozymes specific to liver, rather than bone)  
o  Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min /1.73 m2 as estimated by the 
Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation   
9. Systolic blood pressure (BP)  90-180 mmHg 
10. Distance walked during each of the two Screening 6MWTs is > 100 meters and <600 meters   
11. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug and must agree to use highly effective physician -approved contraception ( Appendix 2) from Screening 
to 90 days following the last study drug administration  
12. Male subjects must be surgically sterile or must agree to use highly effective physician -
approved contraception ( Appendix 2) from Screening to 90 days following the last study 
drug administration  
13. Ability to understand and willingness to sign an ICF prior to initiation of any study 
procedures 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 42 of 111 4.2 Exclusion Criteria  
Subjects must not meet any of the following criteria: 
1. Diagnosis of non-AL amyloidosis 
2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma 
(Appendix 3)  
3. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject’s ability to safely receive treatment or complete study assessments  
4. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6  months prior to the Month 1- Day 1 
Visit  
5. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area <1.0 cm
2) or severe 
congenital heart disease  
6. ECG evidence of acute ischemia or active conduction system abnormalities with the exception  of any of the following: 
o First degree atrioventricular (AV) block 
o Second degree AV block Type 1 (Mobitz Type 1/Wenckebach type) 
o Right or left bundle branch block 
o Atrial fibrillation with a controlled ventricular rate  (uncontrolled [i.e., >110 bpm] 
ventricular rate is not allowed [determined by an average of three beats in Lead  II or 
3 representative beats if Lead II is not representative of the overall ECG])  
7. Has not recovered (i.e., equivalent to a CTCAE ≥ Grade 2 ) from the clinically significant 
toxic effects of prior anticancer therapy . Exception:  subjects with prior bortezomib treatment 
may have CTCAE Grade 2 neuropathy. 
8. Received any of the following within the specified time frame prior to the Month 1 -Day 1 
Visit:  
o Oral or intravenous antibiotics, antifungals, or antivirals within 1 week, with the 
exception  of prophylactic oral agents . Note:  In the event that a subject requires the 
chronic use of antivirals, Medical Monitor permission is required for  entry into the study.  
o Hematopoietic growth factors, transfusions of blood or blood products within 1 week 
o Chemotherapy , radiotherapy , or other plasma cell directed therapy  within 6 months 
o ASCT within 12 months 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 43 of 111 o Major surgery within 4 weeks 
o Planned major surgery or organ transplant during the study 
o Any other investigational agent within 4 weeks 
o Prior treatment with NEOD001, 11-1F4, anti-SAP antibody ( exception:  allowed as part 
of established diagnostic procedures s uch as SAP scintigraphy) , or other investi gational 
treatment directed at  amyloid  
o Doxycycline within 6 weeks 
9. Active malignancy with the exception of any of the following: 
o Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical 
cancer  
o Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥ 2 years  
o Low-risk prostate cancer with Gleason score <7 an d prostate- specific antigen 
<10 mg/mL  
o Any other cancer f rom which the subject has been disease- free for ≥2 years  
10. History of Grade ≥ 3 infusion- related AEs or hypersensitivity to another monoclonal antibody 
11. History of severe allergy to any of the compo nents of NEOD001 such as histidine/L- histidine 
hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 
12. Currently known uncontrolled bacterial, viral, fungal,  HIV, h epatitis B , or hepatitis C 
infection  
13. Women who are breastfeeding  
14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by participating in the study  
15. Unable or unwilling to adhere to the study-specified procedures and restrictions 
16. Subject is under legal custodianship 
17. Waldenström's macroglobulinemia and/or immunoglobulin M (IgM) monoclonal gammopathy  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 44 of 111 4.3 Early Treatment Discontinuation  
If the subject discontinues study drug prior to the EOS Visit, they should return for an ETD Visit 
30 (± 5) days after their final administra tion of study drug as per Section 6.2. If a subject fails to 
return for the scheduled visit, a documented effort must be made to determine the reason. If the subject cannot be reached by telephone after 2 attempts,  a certified letter will be sent to the 
subject (or the subject’s legally authorized representative, if appropriate) requesting contact with the Investigator . This information will be recorded in the study records. 
If the subject discontinues study drug prior to the EOS , but is willing to continue to participate in 
study visits, the subject should have an ETD Visit 30 (±5) days after his/her final administration of study drug (per Section 6.2) and then have assessments monthly, through Month 12 per Appendix 13. The subject will not have an EOS Visit.  The most important visit is the Month 12 -
Day 1 Visit, so if a subject is unwilling to continue monthly visits, e very effort should be made 
for the subject to return to the clinic and complete the Month 12-Day 1 Visit on schedule. All visits after the ETD Visit should occur on schedule, that is, at the time when their visit would have occurred had they remained on study drug. Following the Month 12- Day 1 Visit, subjects 
will be followed for vital status per Section  6.4. 
Reasons for early  discontinuation from study drug treatment may include, but are not limited to: 
• Hematologic progression and  initiation  of chemotherapy  is required; chemotherapy regimen 
should be documented on the appropriate electronic case report form (eCRF ). 
• Need for organ transplant or major surgery. 
• A suspected NEOD001 -related immunologic reaction  – collect additional serum sampl es, if 
possible, during the period following the treatment stoppage to allow for the determination of the persistence of anti -NEOD001 antibodies. At a minimum, samples should be collected at 
the ETD Visit and 3 months after the ETD Visit, if the subject ag rees to return to the clinic .  
• Occurrence of an AE  or clinically significant laboratory abnormality that, in the opinion of 
the Investigator, warrants the subject’s permanent discontinuation from study drug treatment ; 
the Medical Monitor should be notified as soon as possible of any discontinuation of study drug due to an AE. 
• Suspected or confirmed pregnancy or nursing during study treatment period. Female subjects whose pregnancy test is positive at the ETD Visit must be followed to term or until termination of the pregnancy ( Section 7.4.2). 
At any point in the study, if the subject is unwilling to return to the clinic for further visits but is willing to discuss their health status by phone, follow-up phone calls should be made to the subject or their caregiver every 3 months ( Section  6.4). 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 45 of 111 4.4 Early Termination from the Study  
Early termination occurs if the subject fails to complete the entire study, through the EOS Visit. 
Subjects may withdraw their consent to participate in this study at any time without prejudice. The Investigator must withdraw from the study any subject who requests to be withdrawn. A subject’s participation in the study may be discontinued at any time at the discretion of the Investigator in accordance with his/her clinical judgment. The Sponsor or its designee should be notified in a timely manner of all subject discontinuations.  When possible, the tests and 
evaluations listed for the ETD Visit should be carried out. 
Early termination from the study may occur if:  
• In the opinion of the Investigator, the subject cannot safely participate in the procedures 
required by the protocol 
• Subject withdraws consent 
• Subject is unwilling or unable to comply with the study requirements  
• Subject is lost to follow -up 
Prothena reserves the right to discontinue the study at any time for any reason, including but not 
limited to, clinical or administrative reasons, or to discontinue participation of an individual Investigat or or site for any reason, including but not limited to, poor enrollment or 
noncompliance. 
Vital status will be collected within legal and ethical boundaries for all randomized subject s 
receiving at least one dose of study drug and will be searched in publ ic sources. During the study 
close-out period, survival status will be collected within legal and ethical boundaries for all 
randomized subject s who withdrew participation from the study.  If vital status is determined, the 
subject  will not be considered lost to follow-up. 
4.5 Replacement of Subjects  
Randomized subjects who drop out of the study for any reason will not be replaced. 
4.6 Termination of the Clinical Study  
If the Investigator, the Sponsor or its designee, or the Medical Monitor becomes aware of 
conditions or events that suggest a possible hazard to subjects if the clinical study continues, then the clinical study may be terminated. The clinical study may also be terminated at the Sponsor’s discretion in the absence of such a finding, at any time and for any reason.  
Conditions that may warrant termination of the clinical study include, but are not limited to:  
• The discovery of an unexpected, relevant, or unacceptable risk to the subjects enrolled in the clinical study  
• Failure to enroll subjects at the requ ired rate  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 46 of 111 • A decision by the Sponsor to suspend the study, or to suspend or discontinue development of 
the study drug, for any reason 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 47 of 111 5 TREATMENT OF SUBJECTS 
5.1 Study Drug  
Study drug consists of NEOD001 or placebo. 
5.1.1 Formulation, Packaging, and Labeling of NEOD001  
The active study drug, NEOD001, is supplied as a sterile, lyophilized dosage form in a 20/25 mL 
vial containing 500 mg/vial NEOD001. After reconstitution with 9.6 mL of sterile water for 
injection (WFI), the vial will contain 50 mg/mL of NEOD001, 25 mM L -Histidine,  230 mM 
Trehalose, and 0.02% Polysorbate 20.  
The labelling will comply with applicable regulatory requirements.  
5.1.2 Shipping, Storage, and Handling  of NEOD001 
NEOD001 will be shipped to clinical sites in individual cartons (one vial per carton). Upon receipt, a study staff member will place the NEOD001 in a refrigerator at a temperature ranging from 2 °C to 8°C in a secure, locked location. Access to the NEOD001  should be strictly limited 
to the Unblinded Pharmacy Staff. Neither the Investigator nor any member of the study staff will 
distribute any of the study supplies to any person who is not participating in this study. 
If a study staff member becomes aware that the NEOD001  has not been properly handled ( e.g., 
physical damage to carton/vial, temperature outside the 2°C to 8°C range in transit, or not stored 
at 2°C to 8°C in the clinic ), follow the procedure outlined in the Pharmacy Manual or 
immediately  contact the Unblinded Monitor (contact information available in the Study Manual ). 
In such an event, NEOD001  should be quarantined in a 2°C to 8°C refrigerator and must not be 
administered to any subject until the drug has been approved for use. 
It is expected that the site staff will maintain refrigerator temperature logs in the investigational 
product storage area, recording the temperature at least once each working day.  
See Section  5.3 and the Pharmacy Manual for further details about shipping, storage and 
handling of NEOD001. 
5.2 Accountability and Return of Study Supplies  
The study drug will be dispensed at the discretion of the Investigator under the direction of the 
Unblinded Pharmacy Staff , in accordance with the conditions specified in this protocol. It is the 
Unblinded Pharmacy Staff’s responsibility t o ensure that accurate records of study drug  
disposition and return are maintained. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 48 of 111 5.3 Dosa ge, Preparation, and Administration  
Study drug consists of NEOD001 or placebo. The NEOD001 dose is 24 mg/kg; however, the 
maximum dose administered is not to exceed 2500 mg. Therefore , subjects with a weight of 
104.2 kg or greater will receive the maximum dose of 2500 mg. The subject’s weight during Screening may be used for calculation of the first dose. Subsequent doses may be calculated based on the current weight at  that visit or using the Screening  weight, based on the site’s 
institutional guidelines . A change of ±10 % from the weight being used for dosing should trigger 
recalculation of the dose based on the new weight unless thought to be exclusively due to fluid fluctuation ( e.g., edema) . 
Each vial of 500 mg of NEOD001 will be reconstituted with  9.6 mL sterile WFI to a 
concentration of 50 mg/mL resulting in a buffered, isotonic, preservative-free solution with a total extractable volume of 10 mL. Study drug will be prepared in a 250 mL IV bag of 0.9% saline . The equivalent volume of reconstituted NEOD001 will be withdrawn prior to transferr ing 
the drug solution into the IV bag, such that the total IV bag volume will be 250 mL. A separate placebo will not be provided for this study. Subjects who receive placebo will be administered a 250 mL IV bag of 0.9% saline, which will look identical to the NEOD001 infusion bag. Refer to the Pharmacy Manual for complete information on preparing and administering the study drug.  
The Unblinded Pharmacy Staff  at each site will be responsible for preparing the study drug; all 
other study team members , including the Sponsor and site monitor must remain blinded to study 
drug assignment . The Unblinded Pharmacy Staff will obtain the treatment assignment 
information from the IWRS , and will then prepare and reconstitute the study drug, providing it to 
the Investigator for administration . The Unblinded Pharmacy Staff will maintain the records for 
drug accountability for audits or inspections.  An Unblinded Monitor will be assigned as the 
Sponsor’s designee to perform drug accountability and as such, will be the Unblinded Pharmacy 
Staff’s primary point of contact for any study drug- related issues.  
The study drug should only be administered in settings where emergency resuscitative equipment and personnel trained in the management of anaphylaxis are immediately available to treat systemic reactions under the direct supervision of a physician.  
Study drug will be administered as an initial 120 (± 10)-minute IV infusion on Month 1- Day 1. If, 
in the opinion of the Investigator, the subject tolerates the initial administration , subsequent 
infusions may be administered over 60 (±10) minutes once every 28  (±5) days ; a minimum of 
21 days between doses is required. Subjects may receive up to 12 infusions of study drug.  NEOD001 contains no antimicrobial preservatives . Once reconstituted, storage of study drug, 
inclusive of dilution and administration, should be limited to 24 hours under refrigerated condit ions 
or 4 hours at room temperature. If it is anticipated that the infusion will extend beyond 4 hours, 
the reconstituted study drug should be split into multiple bags to ensure that no amount of 
reconstituted  study drug will be at room temperature for longer than 4 hours (i.e., from the time 
of reconstitution of the vial to end of the infusion of a bag). The additional bag(s) should remain refrigerated until ready for use. The volume contained in the administration tubing should be completely flushed using approximately 30 mL of 0.9% Sodium Chloride Injection (USP) after administration of study drug. The infusion line should NOT be used for blood draws. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 49 of 111 All subj ects will be closely monitored  for approximately 90 (±10) minutes  after completion of 
the study d rug infusion. The Investigator may increase this standard monitoring time if deemed 
appropriate or per local standards. In the event of any clinical concerns or suspicious signs or 
symptoms after the infusion, the subject will remain under observation for as long as the Investigator deems it appropriate.  Beginning with the third infusion, the I nvestigator may 
decrease the monitoring time to no less than 60 minutes, if no infusion- related reactions were 
observed in the previous infusions and allowed per the Institutional Review Board/Institutional 
Ethics Committee ( IRB/ IEC). 
5.4 Dosage Adjustments 
5.4.1 Withholding of Study Drug  
Subjects with symptomatic orthostatic hypotension  and/or systolic BP <85 mmHg, which in the 
medical judgment of the Investigator would interfe re with subject’s ability to safely receive 
study drug, will have study drug withheld  until the next scheduled monthly administration, but 
should still have all other study visit assessments completed . 
5.4.2 Management of Suspected Systemic Infusion -Related /Hypersensitivity  Adverse 
Events  
In the event of a suspected systemic infusion-related and/or hypersensitivity AE, the infusion 
should be immediately discontinued and appropriate supportive therapy should be administered per institutional practic e, which may include, but is  not limited to,  epinephrine, IV fluids, 
corticosteroids, vasopressors, oxygen, bronchodilators, antihistamines, or 
acetaminophen/paracetamol . Subjects should be evaluated and carefully monitored until there is 
complete resolution of the AE (i .e., all  hypersensitivity signs and symptoms have resolved) . In 
addition to the institution’s recommended assessments, blood samples should be obtained in the 
event of a suspected systemic infusion-related and/or hypersensitivity AE for assessment of the following: cytokine levels (IL -6, IL -8, TNF-alpha, and INF- gamma)  complements C3 , C4, and 
CH50 ; C-reactive protein ( CRP ), serum amyloid A/ acute phase serum amyloid  A (SAA/A-
SAA); tryptase (serial levels: within 30 to 120 minutes of onset AND at 48 to 72 hours); serum NEOD001 ; and anti-NEOD001 antibody levels. 
For subjects with a Grade 2 infusion-related AE, if it is appropriate to restart the infusion, the infusion rate should be decreased by 50% ( e.g., if the infusion wa s previously administered over 
60 min utes, the new rate should be based on administering 250 mL over at least 90 minutes) . If 
the subject is to receive additional infusions in subsequent weeks, the rate of these infusions should be discussed with and agreed upon prospectively by the Investiga tor and the Medical 
Monitor. In addition, for all subsequent infusions, maximal premedication must be administered 
according to institutional practice and should include an H1 blocker, an H2 blocker, an antipyretic such as acetaminophen/paracetamol and a s teroid (e.g., 25- 50 mg hydrocortisone IV).  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 50 of 111 If a subject experiences a Grade 3 infusion -related and/or hypersensitivity  AE, the infusion 
should not be restarted. The decision to continue dosing this subject at their next scheduled 
administration should be d iscussed with the Medical Monitor. If the decision is made to proceed 
with subsequent dosing, both  the dose and infusion rate will be reduced by  50% from the 
original dose (i.e., 12.5 mg/kg in 250 mL) and  infusion rate (i.e., over at least 90 minutes [if the 
previous infusion time was 60 minutes]). In addition, maximal premedication  must be 
administered  according to institutional practice and should include an H1 blocker, an H2 blocker, 
an antipyretic such as acetaminophen/paracetamol  and a steroid (e.g., 25-50 mg hydrocortisone 
IV). Subjects who have an infusion- related and/or hypersensitivity AE at the subsequent 
scheduled study drug administration must have study drug permanently discontinued and have an ETD Visit per Section 6.2. 
Subjects who experience a Grade 4 infusion -related and/or hypersensitivity AE must have study 
drug permanently discontinued and have an ETD Visit per Section  6.2. 
5.4.3 Dose Reductions  
Dose reductions may be allowed in the event that AEs are observed that are believed to be 
related to study drug, and which in consultation between the Investigator and the Medical Monitor, may be managed by a 50% reduction in dose. The duration of the dose reduction will be at the Investigator’s discretion. 
5.5 Treatment Compliance  
Treatment compliance will be documented in the eCRF by recording the date, time, and whether 
or not each IV dose of study drug was completely infused, along with reasons why treatment was adjusted or not administered, if applicable. 
5.6 Prior and Concomitant Medication/Therapy  
Prior and concomitant medications include any drug (investigational, prescription, or over-the-counter) or biological product (such as vaccines, blood or blood components) including herbal remedies or preparations . All prior/concomitant medications taken or received by a subject 
within the 28 days prior to the Month 1-Day 1 Visit through the EOS /ETD Visit, and any 
changes to concomitant medications during the study will be re corded on the appropriate eCRF. 
5.6.1 Allowed  (Concomitant)  
• Radiation therapy for the treatment of local amyloid deposits  
• Calcium channel blockers (if on stable dose) 
• Steroids ( exception:  not allowed for treatment of AL amyloidosis) 
5.6.2 Prohibited  (Concomitant) 
• Chemotherapy  
• Other investigational agents  (e.g., drugs not approved for any indication) 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 51 of 111 • Myeloablative chemotherapy with ASCT  
• Organ t ransplant 
• Histone deacetylase (HDAC) inhibitors 
• Doxycycline  use (if required for treatment of infection, contact the Medical Monitor)  
• Gadolinium contrast agents are only permitted in exceptional circumstances. If a patient 
requires the use of gadolinium contrast agents, contact the Medical Monitor. 
• Experimental imaging of amyloid   
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 52 of 111 6 STUDY PROCEDURES  
6.1 Evaluations by Visit  
6.1.1 Screening  
With the exception of the assessments to be considered standard of care (e.g., NT- proBNP/BNP, 
tissue samples, and echocardiograms), a signed ICF must be obtained before any study- specific 
screening evaluations are performed and should be documented in the subject’s medical chart.  
Screening evaluations and procedures will be performed within 28 days prior to the first study 
drug administration on Month 1- Day 1.  Individual test results that do not meet eligibility 
requirements may be repeated, with the exception  of 6MWT; full r escreening is allowed once 
per subject.  
The following will be performed within the 28 days prior to the Month 1- Day 1  Visit: 
• Signed  ICF 
• Review inclusion and exclusion criteria to assess eligibility  
• Medical History - Obtain comprehensive cardiac, hematologic , and oncologic medical 
history; additionally , for all other conditions obtain relevant medical history for the past 
5 years (including all major hospitalizations and surgeries), as well as the subject’s current 
medical status  
• If availabl e, record r esults of a t least 2 prior NT -proBNP or 2 prior BNP  measures from 
within the previous 6 months ; NT-proBNP is preferred, but BNP may be used if it is the 
institution’s historical standard  
• Prior and concomitant medications/therapy 
• Assessment of AE s 
• Confirmation of AL amyloidosis by mass spectrometry tissue typing, immunoelectron 
microscopy, gene sequencing, and/or 99mTc scintigraphy  for subjects who meet Inclusion 
Criterion #3 
• Complete physical examination - including height, weight, and examination of general appearance; head, ears, eyes, nose, and throat; neck; skin; cardiovascular system; respiratory 
system; gastrointestinal system; and nervous system. The following should be assessed:  macroglossia, submandibular nodes/fullness, adenopathy, ecch ymoses, liver/spleen size 
(palpable +/ -), ascites (+/ -), and edema (which should be quantified on a scale of 0-4).  
• Vital signs – heart rate (HR), BP, respiratory rate (RR) , and body temperature after the 
subject has been at rest for ≥ 5 minutes 
• ECOG PS ( Appendix 7)  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 53 of 111 • NYHA class ( Appendix 8)  
• NIS-LL (Appendix 5 and Section  6.6.2.5) and VASPI  (Appendix 6 and Section 6.6.2.5) 
o Note: NIS -LL is for all subjects with peripheral neuropathy at Screening  and the addition 
of the VASPI  is only for subjects with painful peripheral neuropathy at Screening  
• SF-36v2 ( Appendix 9) 
o Note: A dminister SF -36v2 before  conducting any other assessments  on the same calendar 
day it is administered  
• KCCQ  (Appendix 10)  
o Note: A dminister KCCQ after the SF -36v2, but before  conducting an y other assessments 
on the same calendar day it is administered  
• 6MWT ( Section 6.6.2.3) ; collect HR and BP pre- and post- 6MWT administration  
o Notes: Two pretreatment 6MWTs are required before the first administrat ion of study 
drug, with a minimum of 4 days in between the two tests. The first Screening 6MWT is 
required to be performed between Days -28 and -5, at least 4 days prior to the second Screening 6MWT, which should be performed within 2 days prior to Month 1- Day 1 
(i.e., on Day - 2 or Day -1). NT-proBNP should be drawn before conducting 6MWT if 
being performed on the same calendar  day. 
• Echocardiogram (perform locally) 
o Note: If an echocardiogram wa s conducted within 90 days prior to Screening Day -28, it 
does not need to be repeated during Screening and the previous result may be used for eligibility ; however, to be eligible for  the additional cardiac imaging analysis , the 
subject  must have had a 4-chamber view, 2-dimensional echocardiogram with Doppler 
• 12-lead ECG performed in triplicate (perform  centrally ) 
• Laboratory Assessments (central laboratory, unless otherwise noted): 
o Hematology  and c hemistry  (including amylase  and creatine kinase) per Appendix 11  
o PT/INR and PTT  
o Additional coagulation samples per  Appendix 12  
o Troponin T 
o NT-proBNP  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 54 of 111  Note: NT -proBNP should be drawn before 6MWT if being performed on the same 
calendar day 
o Serum pregnancy test for WOCBP within 28 days before Month 1-Day 1 study drug 
admi nistration  
 Note: W omen with tubal ligations are considered to be of childbearing potential but 
women who are surgically sterile ( hysterectomy ) or postmenopausal ≥ 2 years are not 
considered to be of child bearing potential  
o Serum f ree light c hains  
o Serum immunofixation electrophoresis (IFE) and protein electrophoresis (PEP) 
o Urinalysis  - dipstick  per Appendix 11  
o Urinalysis - quantitative analysis/renal biomarkers per Appendix 11  
 Note s: It is important that the sample be taken before exercising and at approximately 
the same time for each collection; therefore, the first morning void is recommended. 
Urine samples will be collected and frozen for potential analysis at a later date.   
o 24-hour urine collection for: 
 Urine IFE and PEP 
 Urine  protein excretion  
• Other Assessments (see Laboratory Manual)  
o  Archive sample – collect only from those subjects who have consented to the collection 
and archiving of their samples for future correlative testing  
6.1.2 Treatment Visits  
Study visits will occur every 28 days based on scheduling from Month 1-Day 1. A ±5- day 
window is allowed for visits starting after Month 1. Subjects may recei ve up to 12 infusions of 
study drug ; a minimum of 21  days between doses is required. 
The predose assessments for each visit may be performed within the 3 days before the visit  unless otherwise specified. Although central laboratory assessments will be per formed each 
month for study analysis, local laborat ory assessments may be performed for subject 
management  when necessary for obtaining results on a more immediate basis . Results  will be 
reviewed p rior to dosing at each month’s Day 1 visit to confirm that continued dosing is 
appropriate.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 55 of 111 Subjects who present with symptomatic orthostatic hypotension and/or systolic BP <85 mmHg, 
which in the medical judgment of the Investigator would interfere with the subject’s ability to 
safely receive treatment,  will have study drug withheld until the next scheduled monthly 
administration, but should still have all other study visit assessments completed . If study drug is 
withheld and subsequently re scheduled , central laboratory  assessments required for that visit will 
need to be repeated  if they were drawn  >7 days prior to the re scheduled dosing date. However, a 
symptom- directed physical exam  and vital signs need to be repeated prior to each dosing.  
6.1.2.1 Month  1-Day 1 
Prior to  Study Drug Infusion: 
The following assessments will be done prior to dosing on Month 1- Day 1 : 
• Concomitant medications/therapies  
• Assessment of AEs  
• Directed physical examination - including weight and examination of the following:  general appearance; head, ears, eyes, nose, and throat; neck; skin; cardiova scular system; respiratory 
system; gastrointestinal system; and nervous system. The components of the physical exam will be as clinically indicated; h owever, the following should be assessed:  macroglossia, 
submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen size (palpable +/ -), 
ascites (+/ -), and edema (which should be quantified on a scale of 0-4 ).  
• Vital signs including HR, BP, RR, and body temperature (per Section  6.6.1.2) – within 
30 minutes b efore dosing, aft er subject has been at rest ≥5 minutes; assess in same position 
for all time points  
• ECOG PS ( Appendix 7) 
• NYHA class ( Appendix 8) 
• NIS-LL (Appendix 5) and VASPI ( Appendix 6) 
o Note: NIS -LL is for all subjects with peripheral neuropathy at Screening  and the addition 
of the VASPI  is only for subjects with painful peripheral neuropathy at Screening  
• 12-lead ECG in triplicate (perform centrally ) within  30 minutes before study drug 
administration  
• Laboratory Assessments  (central laboratory, unless otherwise noted): 
o Hematology  and c hemistry  (including amylase)  per Appendix 11 
o Inflammatory biomarkers per  Appendix 11  
o NT-proBNP  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 56 of 111 o Serum  pregnancy test within 24 hours before study drug administration (local laboratory) 
o Urinalysis - dipstick  per Appendix 11  
• Other Assessments (see Laboratory Manual)  
o NEOD001 serum sample – wit hin 2 hours before infusion 
o Anti-NEOD001 serum sample 
• Randomization – After the subject is randomized, study drug treatment may be initiated   
• Ensure subject continues to meet eligibility criteria before administration of study drug  
Study Drug Administratio n: 
• Administer study drug IV over 120 (± 10) minutes ( Section  5.3) 
• Vital signs including HR, BP, RR, and body temperature  (per Section  6.6.1.2) – assess 
60 (±10) minutes after the start of the infusion; assess in same position for all time points  
Assessments A fter I nfusion:  
• Monitor subjects for 90 (±10) minutes following completion of the study drug infusion. The 
Investigator may increase this standard monitoring time if deemed appropriate or per local 
standards. In the event of any clinical concerns or suspicious signs or symptoms after the infusion, the subject will remain under observation for as long as the Investigator deems it appropriate. 
• Vital signs including HR, BP, RR, and body temperature  (per Section 6.6.1.2) after subject 
has been at rest ≥5 minutes; assess in same position for all time points : 
o At the end of infusion (EOI) (+5 minutes) 
o 30 (±5) minutes after EOI 
o 60 (± 10) minutes after EOI 
• 12-lead ECG in triplicate (perform centrally ): 
o Within 15 minutes after EO I 
• Other Assessments (see Laboratory Manual):  
o NEOD001 serum sample within 4 hours after EOI  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 57 of 111 o Collect a dditional blood samples if a significant toxicity is observed (e.g., a systemic  
infusion- related reaction , anaphylaxis, hypersensitivity reaction; Section  5.4.2) and if 
possible, samples should be collected while the acute symptoms persist 
• Discharge subject from clinic if no immediate safety concerns and/or hypersensitivities are 
present after the postdose assessments and monitoring period. In the event of any clinical 
concerns or suspicious signs or symptoms after the infusion, the subject will remain with the 
Investigator and study staff for further observation until the Investigator deems the subject can safely leave the clinic.  
6.1.2.2 Month s 2 through 12 – Day 1 (±5 Days) 
Prior to Study Drug Infusion:  
The following assessments will be done prior to dosing on Day 1: 
• Concomitant medications/therapies  
• Assessment of AEs  
• Directed physical examination - including weight and examination of the following:  general 
appearance; head, ears, eyes, nose, and throat; neck; skin; cardiovascular system; respiratory system; gastrointestinal system; and nervous system. The components of the physical exam will be as clinically indicated; h owever, the following should be assessed:  macroglossia, 
submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen size (palpable +/- ), 
ascites (+/ -), and edema (which should be quantified on a scale of 0-4 ).  
• Vital signs including HR, BP, RR, and body temperature  (per Section  6.6.1.2) – within 
30 minutes before dosing, after subject has been at rest ≥5 minutes;  assess in same position 
for all time points  
• ECOG PS ( Appendix 7) 
• NYHA class ( Appendix 8) 
• NIS-LL (Appendix 5) and VASPI ( Appendix 6) – Months 3, 6, 9, 12 
o Note: NIS -LL is for all subjects with peripheral neuropathy at Screening and the addition 
of the VASPI  is only for subjects with painful peripheral neuropathy at Screening  
• SF-36v2 ( Appendix 9) – Months 3, 6, 9, 12 
o Note: administer SF -36v2 before performi ng any other study assessments  on the same 
calendar day it is administered  
• KCCQ ( Appendix 10) – Months 3, 6, 9, 12 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 58 of 111 o Note: Administer after the SF -36v2, but prior to conducting any other assessments on the 
same calendar day it is administered  
• 6MWT ( Section 6.6.2.3) and collect HR and BP pre- and post-6MWT administration – 
Months 3, 6, 9, 12 
o Notes: NT -proBNP should be drawn before conducting 6MWT if being performed on the 
same calendar  day. If the 6MWT is conducted on the same calendar da y as the study 
drug infusion, the 6MWT must be completed before initiation of the infusion 
• Echocardiogram (perform locally) – Month 12 only 
o Note s: May be conducted within 10 days before Day 1. To be eligible for the additional 
cardiac imaging analysis , the subject must have a 4 -chamber view, 2-dimensional 
echocardiogram with Doppler. 
• 12-lead ECG in triplicate (perform centrally ) – within 30 minutes before dosing – Months 3, 
6, 9, 12 
• Laboratory Assessments  (central l aboratory, unless otherwise noted): 
o Hemato logy and c hemistry (including amylase  and creatine kinase) per  Appendix 11  
o PT/INR and PTT  
o Additional coagulation samples if clinically indicated, per  Appendix 12 
o Inflammatory biomarkers per  Appendix 11 – Month 3 
o Troponin T 
o NT-proBNP  
 Note: NT -proBNP should be drawn before conducting 6MWT if being performed on 
the same calendar day (i.e., at Months 3, 6, 9, 12) 
o Serum pregnancy test (WOCBP only; local laboratory) 
o Serum free light chain  – Months 3, 6, 9, 12 
o Serum IFE and PEP – Months 3, 6, 9, 12 
o Urinalysis - dipstick per Appendix 11 – Months 3, 6, 9, 12 
o Urinalysis - quantitative analysis/renal biomarkers per  Appendix 11 – Months 3, 6, 9, 12 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 59 of 111  Notes: It is important that the sample be taken before exercising and at approximately 
the same time for each collection; therefore, the first morning void is recommended. Urine samples will be collected and frozen for potential analysis at a later date.  
o 24-hour urine collection  at Months 3, 6, 9, 12 for: 
 Urine IFE and PEP 
 Urine protein excretion  
• Other Assessments (see Laboratory Manual) : 
o NEOD001 serum sample – within 2 hours before infusion – Months 3, 6, 9, 12 
o Anti-NEOD001 seru m sample  – Months 3, 6, 9, 12 
o Archive sample – Months 6 and 12 
Study Drug Administration:  
Subjects with symptomatic orthostatic hypotension and/or systolic BP <85 mmHg, which in the medical judgment of the Investigator would interfere with subject’s abilit y to safely receive 
treatment, will have study drug withheld.  
• Administer study drug IV over 60 (±10) minutes if the prior infusions were well tolerated 
(Section 5.3) . If needed, see Section  5.4 for dose adjustment instructions. 
• Collect additional blood samples  per Section  5.4.2 if a significant toxicity is observed  
(e.g., a suspected systemic  infusion- related reaction, anaphylaxis, hypersensitivity reaction) 
and if possible, samples should be collected while the acute symptoms persist  
Assessments After Infusion:  
• Monitor subjects for 90 (±10) minutes following completion of the study drug infusion. The Investigator may increase this standard monitoring time if deemed appropriate or per 
local standards. In the event of any clinical concerns or suspicious signs or symptoms after 
the infusion, the subject will remain under observation for as long as the Investigator deems it appropriate. Beginning with the third infusion, the Investigator may decrease the monitoring time to no less than 60 minutes, if no infusion- related reactions were observed in 
the previous infusions and allowed per the IRB/ IEC. 
• Vital signs including HR, BP, RR, and body temperature  (per Section 6.6.1.2) – after subject 
has been at rest ≥5 minutes; assess in same position for all time points : 
o At EOI  (+5 minutes ) 
o 60 (±10) minutes after EOI 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 60 of 111 • 12-lead ECG in triplicate (perform centrally ) – Months 3, 6, 9, 12: 
o Within 15 minutes after EOI  
• NEOD001 s erum sample  – Mo nths 3, 6, 9, 12: 
o Within 4 hours after EOI  
• Discharge subject from clinic if no immediate safety concerns and/or hypersensitivities are 
present after the postdose assessments and monitoring period. In the event of any clinical 
concerns or suspicious signs or symptoms after the infusion, the subject will remain with the 
Investigator and study staff for further observation until the Investigator deems the subject can safely leave the clinic.  
6.2 End of Study /Early Treatment  Discontinuation ( EOS/ETD) :  30 (±5) Days 
AFTER Final Dose  
A final visit should  occur  30 (±5) days after the final administration of study drug . The 
assessments shown for EOS/ETD should also be conducted for any unscheduled visit (i.e., a visit not specified by the protocol) as clinically indicated or if deemed necessary.  
• Concomitant medications/therapy  
• Assessment of AEs  
• Complete physical examination - including weight and examination of general appearance; 
head, ears, eyes, nose, and throat; neck; skin; cardiovascular system; respiratory system; 
gastrointestinal system; and nervous system. The following should be assessed: macroglossia, submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen size (palpable +/ -), ascites (+/ -), and edema (which should be quantified on a scale of 0-4).  
• Vital signs including HR, BP, RR, and body temperature  (per Section  6.6.1.2)  - after subject 
has been at rest ≥5 minutes  
• ECOG PS ( Appendix 7) 
• NYHA class ( Appendix 8) 
• NIS-LL (Appendix 5) and VASPI ( Appendix 6) 
o Note: N IS-LL is for all subjects with peripheral neuropathy at Screening  and the addition 
of the VASPI  is only for subjects with painful peripheral neuropathy at Screening  
• SF-36v2 ( Appendix 9) 
o Note: Administer SF -36v2 before conductin g any other assessments  on the same calendar  
day it is administered  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 61 of 111 • KCCQ ( Appendix 10)  
o  Note: Administer after the SF -36v2, but prior to conducting any other assessments on the 
same calendar day it is administered  
• 6MWT ( Secti on 6.6.2.3) ; collect HR and BP pre- and post- 6MWT administration  
o  Note: NT -proBNP should be drawn before conducting 6MWT if being performed on the 
same calendar  day 
• Echocardiogram – perform  (locally ) if not done within 60 days prior to visit 
o  Note : To be eligible for the additional cardiac imaging analysis , the subject must have a 
4-chamber view, 2-dimensional echocardiogram with Doppler 
• 12-lead ECG performed in triplicate (perform centrally ) 
• Laboratory Assessments (c entral laboratory, unless otherwise noted): 
o Hematology and  c hemistry (including amylase  and creatine kinase) per Appendix 11  
o PT/INR and PTT  
o Additional coagulation samples per Appendix 12  
o Inflammatory biomarkers per Appendix 11  
o Troponin T 
o NT-proBNP  
 Note: NT -proBNP should be drawn before conducting 6MWT if being performed on 
the same calendar  day 
o Serum pregnancy test (WOCBP only) 
o Serum free light chains  
o Serum IFE  and PEP  
o Urinalysis  - dipstick per  Appendix 11  
o 24-hour urine collection for: 
 Urine IFE and PEP 
 Urine  protein excretion  
• Other Assessments (see Laboratory Manual) : 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 62 of 111 o NEOD001 serum sample 
o Anti- NEOD001  serum sample  
6.3 90-day Postdose P regnancy Test  
For WOCBP only: Obtain a local laboratory serum  pregnancy test 90 (±5) days after the last 
administration of study drug. 
6.4 Vital Status  Follow- Up Phone Call  
For randomized subjects who received at least 1 dose of study drug, conduct vital statu s 
telephone call approximately 3 months after last visit and approximately every 3 months 
thereafter or until subject enrolls in a separate open- label study , death, or for up to 5 years. 
6.5 Order of Assessments of Specific Tests  
SF-36v2: 
Whenever the SF-36v2 is required, it should be administered prior to any other visit assessments  
on the calendar day it is administered . 
KCCQ : 
Administer the KCCQ after the SF -36v2, but prior to conducting any other assessments on the 
calendar  day it is administered . 
6MWT: 
Questionnaires and clinical laboratory sample s, including NT-proBNP, should be drawn prior to 
administering the 6MWT, if being performed on the same calendar day. The  post baseline 
6MWTs must be completed before the study drug infusion is initiated, if being performed on the same calendar day.  
ECGs and Vitals:  
When ECGs are scheduled to be performed at the same time point as vital signs (e.g. , within 
30 minutes before dosing), the ECG should be completed before the blood pressure and HR  
measurements .  
ECGs and PK Sampling:  
When ECGs are scheduled to be performed at the same visit as PK blood collection, the ECG should be done before the PK blood collection. 
Concomitant Medications:  
Routine medications should not be administered in the 15 minutes after the completion of the NEOD001 infusion.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 63 of 111 6.6 Methods of Assessment  
6.6.1 Safety  
6.6.1.1 Clinical Laboratory Evaluations 
A central laboratory will be used for this study for analysis of hematology, chemistry  (including 
amylase), coagulation, inflammatory biomarkers, cardiac biomarkers, serum free light chains, 
serum IFE/ PEP, urinalyses, and 24-hour urine collection for urine IFE/PEP and urine protein 
excretion . Central and local pregnancy testing will be conducted as shown in Table 1 . 
Local laboratory results may be obtained at the Investigator’s discretion for subject management 
when necessary for obtaining results on a more immediate basis. Results will be reviewed prior to dosing at each month’s Day 1 visit to confirm that continu ed dosing is appropriate. Results 
from local laboratory tests will not be collected in the eCRFs or the clinical database.  
Citrated plasma samples will be collected and frozen for potential analysis of coagulation indices at a later date. These analyses ma y include but may not be limited to the indices listed in 
Appendix 12. 
Urine samples will be collected and frozen for potential analysis of renal biomarkers at a later 
date (see Appendix 11).
 It is important that the sample be taken before exercising and at 
approximately the same time for each collection; therefore, the first morning void is recommended.  
The 24-hour urine IFE/PEP and 24-hour urine protein excretion tests will be performed using the  
same 24 -hour urine collection sample when required at the same visit. Details regarding the 
24-hour urine sample collection will be provided in the Laboratory Manual. 
A bioanalytical laboratory will be used for the analysis of NEOD001 and anti- NEOD001  
samples, as well as for the storage of serum samples for future correlative testing ( Section s 6.6.3 
and 6.6.4). One or more laboratories will be used for mass spectromet ry of tissue samples, immunoelectron 
microscopy, gene sequencing, and/or 
99mTc scintigraphy, which are required for subjects who 
meet Inclusion Criterion #3.   Details for the processing of laboratory specimens will be provided in the Laboratory Manual. 6.6.1.2 Vital Signs  
Predose vital signs should be assessed within 30 minutes before dosing. Vital signs should be 
measured after the subject has been at rest ≥5 minutes. Within a single visit, assess in the same 
position for all time points.  
Heart rate will be measured from the radial pulse counted manually or with an automatic BP monitor over at least 15 seconds and adjusted per minute.  
Blood pressure (systolic and diastolic) measurements should be taken from the same arm 
throughout the study using an automated BP monitor that uses an oscillometric method .  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 64 of 111 Respiratory rate will be measured over at least 15 seconds and adjusted per minute.  
Body temperature can be measured  using either  oral or tympanic methods, but the method should 
be consistent throughout the study for a given subject.  
Blood pressure and HR are to be collected after ECGs are completed.  
As part of the 6MWT, BP and HR will be collected pre- and post- 6MWT administration.  
6.6.1.3 Physical Examination 
Any unfavorable changes in physical examination findings cons idered by the Investigator as 
clinically significant will be documented in the eCRF as an AE. Physical examinations must be 
performed by the Investigator or a medically qualified delegate.  
A complete physical examination includ es height (Screening only), w eight, and examination of 
the following:  general appearance; head, ears, eyes, nose, and throat; neck; skin; cardiovascular system; respiratory system; gastrointestinal system; and nervous system. A directed physical examination  includes weight and other components, which will be as clinically indicated. At all 
visits, the following are to be assessed: macroglossia, submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen size (palpable +/ -), ascites (+/ -), and edema (which should be 
quantified on a scale of 0 -4). 
6.6.1.4 Echocardiograms 
Echocardiograms will be performed locally. Data from study centers that possess the technical 
abilities to produce a 4-chamber view from a 2- dimen sional echocardiogram with Doppler will 
be used for the relevant exploratory endpoint analysis. Details will be provided in the Study Manual.  Note that the Month 12 echocardiogram may be performed within 10 days before 
Day 1. 
6.6.1.5 12-Lead ECGs 
The ECGs will be performed centrally . Measurements will be made in triplicate, 1 to 10 minut es 
apart  and taken after the subject has rested in a supine position for ≥ 5 minutes. Heart rate, PQ/PR 
duration, QRS duration, QT duration, and  QTcF - Fridericia's correction formula, and the 
Investigator’s overall interpretation will be recorded. When ECGs are scheduled to be performed at the same visit as PK blood collection, the ECG should be done before the PK blood collection. 
6.6.2 Efficacy  
6.6.2.1 Organ Response (i.e., cardiac, renal, peripheral nerve) 
See Appendix 4. 
6.6.2.2 Short Form-36v2® Health Survey ( SF-36v2 ) 
The SF -36v2 should be administered before any other study assessments are performed  on the 
same calendar day it is administered . See Appendix 9. Details will be provided separately.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 65 of 111 6.6.2.3 6-Minute Walk Test  (6MWT)  
The postbaseline 6MWT s may  be administered on the same calendar day that study drug is 
administered, if the 6MWT is completed before initiation of the study drug infusion. The 
questionnaires and clinical laboratory samples (central and if applicable, local ) should be drawn 
prior to administering the 6MWT, if being performed on the same calendar  day. As part of the 
6MWT, BP and HR will be collected pre- and post- 6MWT administration.  Subjects should plan 
to be able to return to the same clinical site for  each 6MWT from first Screening through Month 
12. 
If the subject discontinues study drug prior to the Month 12 Visit, every effort should be made 
for the subject to return to the clinic at the Month 12 time point for completion of all of the Month 12- Day 1  assessments, in particular, the 6MWT.  
Details regarding the requirements for proper administration of the 6MWT are described in the Study Manual.  
6.6.2.4 Kansas City Cardiomyopathy Questionnaire ( KCCQ ) 
The KCCQ ( Appendix 10) should be administer ed after the SF -36v2, but prior to conducting any 
other assessments  on the same calendar day it is administered . Details will be provided in the 
Study Manual. 6.6.2.5 Peripheral Neuropathy Assessment  
Peripheral neuropathy  will be assessed as follows : 
• The Neuropathy Impairment Score in Lower Limbs (NIS- LL; Appendix 5) assesses  lower 
limb reflexes, sensation, and motor strength and will be administered to subjects who have 
peripheral neuropathy at Screening  
• The Visual Analog Scale – Pain Intensity (VASPI ; sample tool in Appendix 6) assesses a 
subject’s level of pain related to peripheral neuropathy and will be administered to subjects who have painful peripheral neuropathy at Screening . Details regarding administration of the 
VASPI are described in the Study Manual.  
Peripheral neuropathy and neuropathic pain AEs will be assessed using NCI- CTCAE grading, as 
shown in Table 2 . 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 66 of 111 Table 2 Common  Terminology Criteria for Adverse Events (CTCAE) Grade 1 -5 for 
Peripheral Neuropathy  and Neuropathic Pain 
 CTCAE Grade  
 1 2 3 4 5 
Peripheral 
motor 
neuropathy  Asymptomatic; 
clinical or diagnostic 
observations only; 
intervention not 
indicated  Moderate 
symp toms; limiting 
instrumental ADL  Severe symptoms; 
limiting self -care 
ADL; assistive 
device indicated  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Peripheral 
sensory 
neuropathya Asymptomatic; loss of 
deep tendon reflexes 
or paresthesia  Moderate 
symptoms; limiting 
instrumental ADL  Severe symptoms; 
limiting self -care 
ADL  Life-threatening 
consequences; urgent 
intervention indicated  Death  
Neuralgia  Mild pain  Moderate 
symptoms; limiting 
instrumental ADL  Severe pain; 
limiting self -care 
ADL    
Abbreviations: ADL = activities of daily living ( e.g., preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.).  
a Definition: a disorder characterized by inflammation or degeneration of the peripheral sensory nerves . 
Source:  National Cancer Institute , 2009. 
 
6.6.3 Pharmacokinetic s 
All subjects enrolled in the study will undergo sparse sampling for serum NEOD001 according 
to Table 1  and the Laboratory Manual. Additional samples should be collected if a significant 
toxicity is observed (per Section  5.4.2). Serum NEOD001 concentrations from this study will be 
pooled with similar samples from other studies in a population PK analysis. Details will be provided in a separate document. Refer to the Laboratory Manual for additional details. 
6.6.4 Immunogenicity  
Serum ADA levels will be measured according to  Table 1  and the Laboratory Manual. 
Additional samples should be collected if a significant toxicity is observed  (per Section 5.4.2). 
ADA levels will be correlated with serum NEOD001 concentr ations when ADA  and 
corresponding serum NEOD001 concentrations are available.  
An electrochemiluminescent (ECL) assay will be used to detect serum anti -NEOD001 
antibodies. Any screening positives will be run at increasing dilutions and a titer determined 
(expressed as the reciprocal of the dilution that generates a positive response). Additionally, all positives will be run in a confirmatory assay to determine the response is specific to NEOD001. 
Refer to the Laboratory Manual for additional details. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 67 of 111 7 ADVERSE EVENTS/SERIOUS ADVERSE EVENTS AND REPORTING  
7.1 Adverse Events —Definition  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related. An AE can , therefore, be any unfavorable and unintended si gn 
(including a laboratory finding, for example), symptom, syndrome, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Examples include:  
• Any treatment -emergent signs and symptoms ( events that are marked by a change from the 
subject’s baseline/entry status [e.g., an increase in severity or frequency of preexisting abnormality or disorder]) 
• All reactions from study drug, abuse of drug, withdrawal phenomena, sensitivity, or toxicit y 
to study drug 
• Apparently unrelated illnesses  
• Injury or accidents 
• Exacerbations of the underlying disease (indication) 
• Extensions or exacerbations or symptomatology, subjective events reported by the subject, 
new clinically significant abnormalities in clinical laboratory, physiological testing, or 
physical examination  
The reporting period for AEs is from the time that the ICF is signed through the last study visit or through 30 days after the last dose of study drug, whichever is later. All AEs, whether o r not 
related to the study drug, must be fully and completely documented on the eCRF and in the subject’s medical notes. The following attributes must be assigned:  description, dates of onset and resolution, severity, assessment of relatedness to study dr ug (either related or not related), 
and action taken. The Investigator may be asked to provide additional follow-up information. 
In the event that a subject is withdrawn from the study because of an AE, it must be recorded on 
the eCRF . The subject should be followed and treated by the Investigator until the AE has 
resolved, stabilized, or a new chronic baseline has been established. 
The Investigator must report all AEs. At each visit the Investigator will ask the subject a 
nonspecific question (e.g., “Have you noticed anything different since your last visit?”) to assess whether any AEs have been experienced since the last report or visit . Adverse events  will be 
identified and documented on t he eCRF in appropriate medical terminology . The severity and the 
relationship to the study drug will be determined and reported on the eCRF ( Sections  7.2 and 
7.3). 
Note that any intermittent or as -needed (“PRN”) use of medication (and specifically any newly 
prescribed medication) during the course of a study may indicate the occurrence of an AE that may need to be recorded on more than one eCRF. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 68 of 111 7.2 Adverse Events —Severity Rating 
Adverse events will be assessed according to CTCAE version 4.0 ( National Cancer Institute, 
2009). A dverse events  that do not have a corresponding CTCAE term will be assessed according 
to their impact on the participant’s ability to perform daily activities as liste d below. The severity 
of each AE should be characterized and then classified into one of five clearly defined categories 
as follows: 
• Grade 1 (mild):  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
• Grade 2 (moderate): Moderate; minimal, local or noninvasive intervention indicated; 
limiting age -appropriate instrumental activity of daily living (e.g., preparing meals, shopping 
for groceries or clothes, using the telephone, managing money).  
• Grade 3 (severe): Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
activities of daily living (e.g., bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden). 
• Grade 4 (life threatening):  Life-threatening consequences; urgent intervention indicated. 
• Grade 5 (fatal): Death related to AE.  
These five categories are based on the Investigator’s clinical judgment, whi ch in turn depends on 
consideration of various factors such as the subject’s reports, the Investigator’s observations, and the Investigator’s prior experience. The severity of the AE should be recorded in the appropriate section of the eCRF. The evaluation of severity is distinguished from the evaluation of “seriousness.” A severe event might not meet the criteria for seriousness and a serious event might be evaluated as mild. For example, a subject might have a severe headache that does not require hospitalization and is consequently not serious ; or a subject might have a mild  
myocardial infarction that requires hospitalization and is, therefore , serious . 
7.3 Adverse Events —Causality Rating 
The causality of each adverse event should be assessed and classified b y the Investigator as 
“related” or “not related.”  An event is considered related  if there is “a  reasonable possibility” 
that the event may have been caused by the product under investigation (i.e., there are facts, evidence, or arguments to suggest possible causation).  
Guidelines for “Related” Events  
• There is clear evidence to suggest a causal relationship, and other possible contributing 
factors can be ruled out. 
• There is evidence to suggest a causal relationship, and the influence of other factors is unlikely.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 69 of 111 • There is some evidence to suggest a causal relationship (e.g., the event occurred within a 
reasonable time after administration of the study drug). However, the influence of other 
factors may have contributed to the event (e.g., the subject’s clinical condition, other concomitant events). 
Guidelines for “Not related” Events  
• There is little evidence to suggest there is a causal relationship. There is another reasonable 
explanation for the event. 
• An adverse event will be considered “not related” to the use of the product if any of the following tests are met:  
o An unreasonable temporal relationship between administration of the product and the 
onset on the AE (e.g., the event occurred either before, or too long after administration of the product for it to be considered product- related)  
o A causal relationship between the product and the AE is biologically implausible (e.g., death as a passenger in an automobile accident)  
o A clearly more likely alternative explanation for the AE is present (e.g., typical adverse reaction to a concomitant drug and/or typical disease- related event)  
Consider the Following When Assessing Causality 
• Temporal associations between the agent and the event 
• Effect of dechallenge and/or rechallenge  
• Compatibility with known class effect  
• Known effects of concomitant medications  
• Preexisting risk factors  
• A plausible mechanism  
• Concurrent illnesses 
7.4 Serious Adverse Events and Unexpected Adverse Events  
In addition to the severity rating, each AE is to be classified by the Investigator as “serious” or 
“not serious.”  The seriousness of an event is defined according to the applicable regulations and generally refers to the outcome of an event . An SAE is one that meets one or more of the 
following: 
• Is fatal  
• Is life -threatening  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 70 of 111 • Is persistent or signifi cantly incapacitating or causes substantial disruption of the ability to 
conduct normal life functions 
• Requires inpatient hospitalization  
• Prolongs existing hospitalization  
• Is a congenital anomaly or birth defect  
• Is an important medical event that may jeop ardize the subject and /or may require medical or 
surgical intervention to prevent one of the outcomes listed above 
Definition of Life -threatening  
An adverse event or suspected adverse reaction is considered "life -threatening" if, in the view of 
either the Investigator or Sponsor (and/or designee) , its occurrence places the subject at 
immediate risk of death. It does not include an adverse event or suspected adverse reaction that, 
had it occurred in a more severe form, might have caused death. 
Definition of Hospitalization  
Hospitalization is defined by the Sponsor as a full admission to the hospital for diagnosis and 
treatment . This includes prolongation of an existing inpatient hospitalization.  
Examples of visits to a hospital facility that do not meet the serious criteria for hospitalization 
include: 
• Emergency room visits  that last for a period of <24 hours and do not result in a full hospital 
admission   
• Outpatient surgery 
• Preplanned or elective procedures  (Section  7.4.1)  
• Protocol procedures 
The above events would not be reported as SAEs unless the event triggering the hospital visit is 
an SAE as defined by other SAE criteria such as life- threatening, results in persistent or 
significant disability/incapacity or as  per medical judgment of the I nvestigator. 
Any other event fulfilling the definition of serious that develops as a result of the in-hospital procedure or extends the hospital stay is an SAE. 
Definition of Disability  
Disability is defined as a persistent or significant incapacity or  substantial disruption of the 
ability to conduct normal life functions. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 71 of 111 Definition of Medically Significant  
Important medical events (medically significant events) that may not result in death, be life -
threatening or require hospitalization may be considered to be an SAE when, based upon 
appropriate medical judgment, they may jeopardize the subject and/ or may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events are a new diagnosis of cancer, intensive treatment in an emergency room or at home for allergic bronchospasm, or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse. 
An SAE may also include any other event that the Investigator or medical monitor judges to be 
serious, or that suggests a significant hazard, contraindication, side effect, or precaution. 
Definition of Suspected Adverse Reactions  
Suspected adverse reaction is considered any AE for which there is a reasonable possibility that 
the drug caused the AE. 
Definition of Unexpected  
An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the 
Investigator Brochure or is not listed at the specificity or severity that has been observed . 
“Unexpected,” as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the Investigator Brochure as occurring with a class of drugs or as 
anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
7.4.1 Elective Procedures and Surgeries  
For the purposes of this protocol, the following conventions will apply for SAE reporting of elective procedures, and surgeries:  
• A prescheduled elective procedure or a routinely scheduled treatment is not to be considered 
an SAE, even if the subject is hospitalized, provided the site stipulates that: 
o The condition requiring the prescheduled elective procedure or routinely schedul ed 
treatment was present before and did not worsen or progress between the subject’s 
consent to participate in the clinical trial and the time of the procedure or treatment  
o The prescheduled elective procedure or routinely scheduled treatment is the sole re ason 
for admission and intervention 
• An untoward medical event occurring during the prescheduled elective procedure or 
routinely scheduled treatment should be recorded as an AE or a SAE. Any concurrent 
medications should also be recorded on the eCRF. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 72 of 111 7.4.2 Other Reportable Information  
In addition, and for the purposes of monitoring, any occurrence of exposure through lactation 
and any pregnancy (with or without an AE) of a female subject or partner of a male subject  
should be reported, regardless of seriousness, according to the directions in Section  7.4.4. Any 
subject who becomes pregnant during the study must be withdrawn from study drug treatment, and will be followed to term.  
7.4.3 Disease Progression and Death  
Disease pro gression (including progression of hematologic condition and/or organ dysfunction of 
AL amyloidosis, and death due to disease progression) is generally recorded as part of the efficacy evaluation and should not be reported as a specific AE or SAE  term . When an AE 
resulting from disease progression meets the requirements to be considered serious, the SAE verbatim term should be reported as the diagnosis that best describes the event rather than as “disease progression.”  For instance, a subject with pleural effusion presents with shortness of breath . The cause of the shortness of breath is a pleural effusion resulting from disease 
progression. The event term may be reported as “pleural effusion” instead of disease progression.  
Death should not be reported as a n SAE  term , but as a clinical outcome of a specific SAE. The 
cause of death, reported on a source document such as the Death Certificate or autopsy report, should be used as the event term for the SAE. For example, in a subject with acute heart failure that results in death, the SAE is reported as “acute heart failure” with an outcome of “death.”   
7.4.4 Serious Adverse Events —Reporting  
It is the responsibility of the Investigator to report SAEs to the Sponsor or its designee within 24 hours of awareness of the event or safety information, whether initial or follow-up. 
All SAEs must be reported immediately (within 24 hours of awareness ) to the Sponsor or its 
designee (see Study Manual for details) . Do not  delay in the reporting of a suspected SAE in 
order to obtain additional information. Any additional information, if collected, can be reported 
to the Sponsor or its designee as a follow-up to the initial report. SAEs will be reported using the SAE forms provided as part of the Study Manual. Please remember to give details of the subject 
identification number or other appropriate terminology and ensure the narrative is comprehensive and includes a chronology and assessment of the event. 
Reporting of SAEs to the IRB/IEC will be done in compliance with the standard operating 
procedures and policies of the IRB/IEC and with applicable regulatory requirements. Adequate information must be obtained by the Sponsor or its designee showing that the IRB/IEC was properly and promptly notified as required. Please refer to the Study Manual  for details on 
reporting SAEs.  
The Investigator is encouraged to discuss any AEs with the Sponsor Medical Monitor for which the issue of seriousness is unclear or questioned. Contact information for the Medical Monitor is listed on the Team Ro ster in the Study Manual. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 73 of 111 The reporting period for SAEs is the period from signing of the ICF through 30 days after the 
last administration of study drug  or last study visit,  whichever is later . SAEs reported to the 
Investigator outside of this reporting period will be reported to the Sponsor or its designee only if, in the judgment of the Investigator, there
 is “a reasonable possibility” that the event may have 
been caused by the product.  
All SAEs  will continue to be followed until the end of the study or  until such events have 
resolved or the Investigator, in conjunction with the Sponsor or its designee, deems them to be 
chronic or stable. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 74 of 111 8 STATISTICAL METHODS AND CONSIDERATIONS  
A statistical analysis plan, providing details about the specific planned analyses and hypothesis 
tests, will be prepared and approved by the Sponsor prior to study database lock and unblinding of double blind subject treatment assignments.  
Endpoints are listed in Section  3.2. 
8.1 Analysis Populations 
The Intent -to-Treat (ITT) Population will include all randomized subjects who receive any 
amount of study drug (NEOD001 or placebo). The ITT Population will be the primary 
population used for efficacy analyses. Treatment assignment will be based on the randomized 
treatment.  
The Safety P opulation will include all subjects who receive any amount of study drug  
(NEOD001 or placebo). The Safety Population will be the primary population used for safety 
analyses . Treatment assignment will be based on the randomized treatment.  
Efficacy Subset Populations:  
The Renal Evaluable Population will include subjects who had renal involvement, i.e., proteinuria >0.5 g/24 hours (measured by 24-hour urine total protein excretion), at baseline and at least one postbaseline assessment of proteinuria.  
The Peripheral Neuropathy Evaluable Population will include subjects who had peripheral nerve 
involvement at baseline (only if the subject had ascending sensorimotor neuropathy due to AL amyloidosis etiologies answered as  yes) and had a baseline Neuropathy Impairment Score–
Lower Limbs (NIS -LL) total score of 2 or greater and at least one postbaseline NIS -LL total 
score.  
The Hepatic Evaluable Population will include subjects who had hepatic involvement defined as >1.5 × ULN  alkaline phosphatase at baseline and at least one postbaseline assessment of alkaline 
phosphatase. 
8.2 Analysis of Study Population and Subject Characteristics  
Enrollment, important protocol deviations, and discontinuations from the study will be 
summarized.  
Demographic and baseline characteristics, such as age, sex, race,  and weight at Screening will be 
summarized using means, standard deviations, medians, ranges for continuous variables, and proportions for categorical variables.  
Study drug administration data will be listed and any dose modifications will be flagged. Study 
drug exposure will be summarized using total number of infusions received, percentage of expected infusions, total dose interruptions and reductions, and dose strength. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 75 of 111 8.3 Analysis of Efficacy Endpoints  
8.3.1 Primary Efficacy Analysis 
The NT -proBNP best response rates in the two arms will be compared using the Cochran-
Mantel -Haenszel  (CMH)  test at the alpha=0.05 (two- sided) level of significance. The analysis 
will be stratified by the randomization  stratification factors.  
8.3.2 Key Secondary Efficacy Analyses 
NEOD001 and placebo will be compared on change from baseline in the SF-36v2 PCS score 
after 12 months of treatment using a REML- based MMRM model including fixed effects for 
randomization strata, trea tment group, categorical time point, and the treatment group × time 
point interaction, and with the baseline value included as a covariate. The unstructured covariance model will be used. The Kenward and Roger method will be used to calculate the denominat or degrees of freedom for the test of fixed effects. All visits will be included in the 
model, with the primary comparison at the EOS Visit to evaluate 12 months of treatment. 
The NEOD001 and placebo distributions of change from baseline in 6MWT distance ( meters) 
after 12 months of treatment will be analyzed using a van Elteren test with stratification by 
randomization strata.  
The analysis of NT -proBNP will be performed using a general linear mixed effects model to 
compare the rate of change ( i.e., slope) o f NT -proBNP over 12 months of treatment between 
treatment groups. The null hypothesis of no difference in slopes between the treatment groups 
will be determined by testing the significance of the treatment group by time interaction term.  
For the primary a nd key secondary efficacy analyses, the overall 2 -sided level of significance 
will be alpha=0.05. The hypothesis testing of key secondary endpoints will be conducted in a sequential closed testing gate-keeping procedure separately, provided the primary eff icacy 
endpoint comparison is statistically significant at an alpha level 0.05. If this comparison is not statistically significant, then the comparison of key secondary efficacy endpoints will be considered nominal, descriptive, and exploratory. This procedure controls the study- wise type I 
error and is described below. 
1. First placebo and NEOD001 will be compared with respect to the primary efficacy endpoint. 
If the comparison achieves statistical significance at the 2 -sided 0.05 level in favor of 
NEOD001, t hen 
2. Placebo and NEOD001 will be compared with respect to change from baseline to 12 months of treatment in the SF -36v2 PCS score. If the comparison achieves statistical significance at 
the 2 -sided 0.05 level in favor of NEOD001, then 
3. Placebo and NEOD001 will be compared with respect to change from baseline to 12 months of treatment in the 6MWT distance (meters). If the comparison achieves statistical significance at the 2 -sided 0.05 level in favor of NEOD001, then 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 76 of 111 4. Placebo and NEOD001 NT-proBNP slopes over 12 months of treatment will be compared.  
If at any step defined above, the comparison is not statistically significant at the 2 -sided 0.05 
level, then the remaining comparisons in the stated hierarchy will be considered nominal, 
descriptive, and exploratory . The study- wise type I error will be maintained with the above 
closed procedure. 
8.3.3 Additional Secondary Efficacy Analyses  
For the Renal Evaluable Population, renal best response will be analyzed in the same manner 
described for the primary efficacy endpoint.  
For the Peripheral Neuropathy Evaluable Population, the change from baseline in NIS -LL total 
score will be analyzed in the same manner described for the SF -36v2.  
For the Hepatic Evaluable Population, hepatic best response will be analyzed in the same manner described for the primary efficacy endpoint. 
8.3.4 Exploratory Efficacy Analyses 
All exploratory quantitative endpoints , except the 6MWT,  defined as the change and percent 
change from baseline will be analyzed in the same manner described for the SF -36v2. 
Exploratory 6MWT endpoints will be analyzed in the same manner described for the key 6MWT 
secondary endpoint.  
Proportion endpoints will be analyzed in the same manner described for the primary efficacy 
endpoint. 
Overall survival and other time -to-event en dpoints will be analyzed in the same manner 
described for progression- free survival.  
8.4 Analysis of Safety Endpoints 
Safety will be assessed through summaries of AE s, changes in laboratory test results, and 
changes in vital signs. Additional safety assessments include 12- lead ECGs. Safety data will be 
summarized by treatment group using the Safety Population. 
All collected AE data will be listed by study site, subject number, and  visit. All AEs occurring on 
or after treatment on Day  1 will be summarized. TEAEs  are defined as AEs or SAEs that occur 
from the initiation of the first study drug infusion through the 30- day period following the last 
dose of study drug. In addition, all SAEs, including deaths, will be listed and summarized 
separately .  
Descriptive statistics of the quantitative laboratory results, vital signs, and ECG parameters will be presented by treatment group and study visit, as well as the change from baseline at each visit.  The baseline value is defined as the last non -missing value before the  initial administration of 
study drug.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 77 of 111 8.5 Analysis of Other Endpoints  
8.5.1 Pharmacokinetic s 
Serum NEOD001 concentrations from this study will be pooled with similar samples from other 
studies in a population PK analysis. Details will be provided in a separate document. 
8.5.2 Immunogenicity  
Serum anti -NEOD001 titers will be listed and correlated with clinical toxicity and serum 
NEOD001 concentrations (where available).  Anti -NEOD001 antibody levels will be correlated 
with NEOD001 exposure level to assess potential dose concentration related associations when anti-NEOD001 antibody  and corresponding PK data are available.  
8.6 Determination of Sample Size  
For the primary endpoint, the assumed true rates for NEOD001 vs placebo are 50% and 22.5%, respectively . Based on a two -sample  comparison of proportions at the alpha=0.05 level of 
significance, a total sample size of 100 subject s (50 in the NEOD001 arm, 50 in the placebo arm) 
will provide >80% power based on a two-sided CMH  test.  Based on the actual enrolled sample 
size (N~130), the final power is 91%. 
8.7 Handling of Dropouts and Missing Data  
Observed data will be included in listings and summary tables. Handling of missing data will be 
outlined in the Statistical Analysis Plan.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 78 of 111 9 DATA RECORDING, RETENTION, AND MONITORING 
9.1 Case Report F orms  
The clinical site(s) participating in this study is (are) required to submit clinical data for each 
enrolled subject via an electronic data capture (EDC) system, using an eCRF . Site personnel will 
be trained on the EDC system before receiving access to the system . The Sponsor or its designee 
is responsible for maintaining a record of all system users. The participants of the study will not be identified by name on any study documents to be collected by the Sponsor. 
All clinical information requested in  this protocol will be recorded on the eCRFs provided by the 
Sponsor or its designee (or via other data collection methods, e.g., electronic laboratory data 
transfer) . The Investigator is responsible for reviewing all eCRFs, verifying them for accuracy, 
and approving them via an electronic signature. Copies of the completed eCRFs, saved to disk in 
pdf format, will be sent to the Investigator’s site at the completion of the study.  
9.2 Availability and Retention of Records 
The Investigator must make study data accessible to the study monitor, other authorized representatives of the Sponsor, and Regulatory Authority inspectors upon request. A file for each subject must be maintained at the clinical site that includes the signed ICF and the Investigator’s copies of all source documentation related to that subject. The Investigator must ensure the reliability and availability of source documents from which the information on the eCRF was derived. 
Investigators are required to maintain all study documentation, includin g documents created or 
modified in electronic format, for at least 15 years following the completion of the study . ICFs 
and adequate records for the receipt and disposition of all study medications must be retained for 
a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated, or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA and other applicable Regulatory Authorities are notified, unless a longer period is required by applicable law or regulation. The Investigator must not discard any records unless given written authorization by the Sponsor. 
Subject identity informat ion will be maintained for 15 years unless applicable law or regulation 
requires a longer period. 9.3 Quality Control and Quality Assurance 
Sponsor representatives and Regulatory Authority inspectors are responsible for contacting and 
visiting the Investigator  for the purpose of inspecting the facilities and, upon request, inspecting 
the various records of the study (e.g., eCRFs and other pertinent data), provided that subject confidentiality is respected.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 79 of 111 The study monitor is responsible for inspecting the eCRFs at regular intervals throughout the 
study to verify the following:  adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research. The monitor should have access to subject medical records and other study- related records 
needed to verify the entries on the eCRFs. The Investigator must agree to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved. 
In accordance with International Committee on Harmonisation (ICH) Good Clinical Practice 
(GCP) and the Sponsor’s (or its designee’s) audit plans, this study may be selected for an audit. Inspection of site facilities (e.g., pharmacy, drug storage areas, laboratories, etc.) and review of study- related records may occur in order to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements. 
9.4 Subject Confidentiality  
The Investigator must ensure that each subject’s anonymity is maintained as described below . On 
the eCRFs or other documents submitted to the Sponsor or its designee, subjects must be 
identified by no more than their date of birth or age, sex, and study- specific site and subject 
numbers. Documents that are not for submission to the Sponsor (e.g., signed ICFs) should be kept in strict confidence by the Investigator in compliance with applicable regulations and ICH GCP Guidelines. The Investigator and institution must permit authorized representatives of the Sponsor, of regulatory agencies, and the IRB/IEC direct access to review the subject’s original medical records for verification of study- related procedures and data. Direct access includes 
examining, analyzing, verifying, and reproducing any records and re ports that are needed for the 
evaluation of the study. The Investigator is obligated to inform the subject in the ICF that the above named representatives may review study -related records from subjects. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 80 of 111 10 ETHICAL AND LEGAL IS SUES  
10.1 Ethical Conduct of the Study  
This study will be conducted in compliance with the current ICH E6 GCP, the ethical principles 
of the Declaration of Helsinki, current FDA GCP guidelines, and any additional national or IRB/IEC or competent authority- required procedures, whichever represents the greater protection 
for the individual. 
10.2 Regulatory Approval 
The Sponsor or its designee will make the appropriate applications to the Regulatory Authority 
in each participating country for regulatory approval of the study and, if necessary, approval to  
import Investigational Product. The study will not start until the required regulatory approvals have been obtained in the appropriate jurisdiction. 
10.3 Ethics Committee Approval  
The Investigator at the site is responsible for obtaining IRB/IEC approval for the final protocol, 
the Sponsor-approved ICF, and any materials used to recruit subjects. Written approval of these documents must be obtained from the IRB/IEC before any subject is enrolled at a site. 
The Investigator is also responsible for the followi ng interactions with the IRB/IEC: 
• Obtaining IRB/IEC approval for any protocol amendments and ICF revisions before 
implementing the changes  
• Providing the IRB/IEC with any required information before or during the study 
• Submitting progress reports to the IRB/IEC, as required, during the conduct of the study; requesting re -review and approval of the study, as needed; providing copies of all IRB/IEC 
re-approvals and relevant communication to the Sponsor or its designee 
• Notifying the IRB/IEC of all serious and u nexpected AEs related to the study medication 
reported by the Sponsor or its designee, as required by local regulations 
10.4 Subject Informed Consent  
The Sponsor or its designee must review and approve the draft ICF and any amended ICFs 
prepared by the Investig ator prior to submission to the IRB/IEC for approval. An 
IRB/IEC -approved copy of the ICF and all amendments will be forwarded to the Sponsor. 
The ICF documents the study-specific information the Investigator provides to the subject and the subject’s agreement to participate . Among other things, the Investigator will fully explain in 
layman’s terms the nature of the study, along with the aims, methods, potential risks, and any discomfort participation in the study may entail. The subject must personally sig n and date the 
ICF before any study -related procedures are performed . The original and any amended, signed 
and dated ICF(s) must be retained in the subject’s file at the study site and a copy of the signed ICF must be given to the subject. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 81 of 111 10.5 Subject Compensa tion for Adverse Effects on Health  
The Sponsor or its designee will adhere to local regulations regarding clinical trial compensation 
guidelines to subjects whose health is adversely affected by taking part in the study.  
10.6 Protocol Amendments and Study Termi nation 
Protocol amendments and amendment to the Informed Consent must be made only with the prior approval of the Sponsor and/or its designee . The IRB/IEC must be informed of all amendments 
and give approval for any amendments likely to affect the safety o f the subjects or the conduct of 
the trial. The Investigator must send a copy of the approval letter from the IRB/IEC to the Sponsor and/or designee. 
Both the Sponsor and the Investigator reserve the right to terminate the study ( Section  4.6), 
according to the study contract . The Investigator should notify the IRB/IEC in writing of the 
trial’s completion or early termination and send a copy of the notification to the Sponsor 
and/or designee. 
10.7 Finance, I nsurance , and I ndemnity  
A study center will not initiate study participation until a fully executed Clinical Study 
Agreement is in place between the study center and the Sponsor. All details associated with finance, insurance, and indemnity are delineated in the Clinical Study Agreement.  
10.8 Publication Policy  
All publication rights are delineated in the Clinical Study Agreement.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 82 of 111 11 REFERENCES  
American Heart Association. Classes of heart failure (last reviewed 06Apr2015). Available from: 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes -of-
Heart -Failure_UCM_306328_Article.jsp. Accessed 31 Oct 2015. 
Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light- chain cardiac amyloidosis from the transthyret in-related familial and senile 
cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. 
Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity 
of recombinant therapeutic proteins in humans. Cur Opin Mol Ther. 2004;6(1):10-6. 
Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose 
melphalan and autologous stem cell transplantation: long -term results in a series of 421 patients. 
Blood. 2011;118(16):4346-52. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials (final version 15Sep2014). Available from: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf . Accessed 
31 Oct  2015. 
Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-92. 
Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with 
adjuvant dexamethasone+/- thalidomide for systemic light-chain amyloidosis: results of a phase II 
trial. Br J Haematol . 2007;139(2):224-33. 
Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light- chain amyloidosis. Leukemia . 2012;26(11):2317-25. 
Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45(6):1115-21. 
Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis . 2010;52(4):347-61. Erratum 
in: Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):445-7. Galat A, Rosso J, Guellich A, et al. Usefulness of (99m)Tc- HMDP scintigraphy for the etiologic 
diagnosis and prognosis of cardiac amyloidosis. Amyloid. 2015(4):210-20. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin 
light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-7. 
Gertz  MA, Landau H, Comenzo RL, et al . First -in-human phase I/II study of NEOD001 in 
patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 
2016(10):1097-103. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 83 of 111 Kaufman GP, Dispenzieri A, Gertz MA, et al . Kinetics of organ response and survival followi ng 
normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 
2015;90(3):181-6. 
Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic 
amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22. 
Michael M, Kastritis E, Delimpassi S, et al. Clinical characteristics and outcome of primary 
systemic light-chain amyloidosis in Greece. Clin Lymphoma Myeloma Leuk. 2010;10(1):56-61. 
National Cancer Institute. Common Terminology Criter ia for Adverse Events v4.0 NCI, NIH, 
DHHS. NIH publication # 09-7473. 28 May 2009. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55. 
Palladini G, Kyle RA, Lars on DR, et al. Multicentre versus single centre approach to rare 
diseases: the model of systemic light chain amyloidosis. Amyloid. 2005;12(2):120-6. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers 
of renal res ponse to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-32. 
Pimm MV, Gribben SJ. Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice. J Cancer Res Clin Oncol. 1992;119(1):41- 5. 
Pinney JH , Smith C J, Taube JB , et al. Systemic amyloidosis in England: an epidemiological 
study. Br J Haematol . 2013;161(4):525-32. 
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. 
Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and 
prognosis of hereditary transthyretin- related cardiac amyloidosis. JACC Cardiovasc Imaging. 
2011;4(6):659-70. 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 84 of 111 12 APPENDICES  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 85 of 111 Appendix 1 Hematologic Response and Progression Criteria 
Response Subcategory  Response Criteria  
Complete Response (CR) • Normalization of free light chain levels and ratio, 
negative serum and urine immunofixation 
Very Good Partial Response (VGPR)*  • Reduction in the dFLC to <40 mg/L (<4.0 mg/dL) 
Partial Response (PR)*  • A greater than 50% reduction in the dFLC 
No Response (NR) • Less than a PR  
Progression • From CR: any detectable monocl onal protein or 
abnormal free light chain ratio (light chain must 
double)  
• From PR, 50% increase in serum M protein to 
>0.5 g/dL or 50% increase in urine M protein to 
>200 mg/day (a visible peak must be present) or 
free light chain increase of 50% to >10 mg/dL 
(100 mg/L)  
Abbreviations:  dFLC = difference between involved and uninvolved free light chains . 
*Only applicable for subjects who had dFLC >50 mg/L (5 mg/dL) prior to treatment. 
Source : Comenzo et al, 2012.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 86 of 111 Appendix 2 Examples of Highly Effective Contraception Methods 
Contraception methods that can achieve a failure rate of <1% per year when used consistently 
and correctly are considered to be highly effective. Such methods include: 
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation1: 
o Oral 
o Intravaginal 
o Transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation1: 
o Oral 
o Injectable  
o Implantable2 
• Intrauterine device (IUD)2 
• Intrauterine hormone- releasing system (IUS)2 
• Bilateral tubal occlusion2 
• Vasectomised partner2,3 
• Sexual abstinence4 
 
1  Hormonal contraception may be susceptible to interaction with the Investigational Medicinal Product (IMP), 
which may reduce  the efficacy of the contraception method.  
2  Contraception methods that in the context of this guidance are considered to have low user dependency.  
3 Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner 
of the women of childbearing potential (WOCBP) trial participant and that the vasectomised partner has received medical assessment of the surgical success.  
4  In the context of this guidance sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferr ed and usual lifestyle of the subject.  
Source:  Clinical Trial Facilitation Group, 2014 . 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 87 of 111 Appendix 3 Revised International Myeloma Working Group (IMWG)  Diagnostic 
Criteria for Multiple Myeloma  
Definition of Multiple Myeloma  
Clonal bone marrow plasma cells ≥10% or biopsy -proven bony or extramedullary 
plasmacytoma* and any one or more of the following myeloma deﬁning events:  
Myeloma deﬁning events:  
• Evidence of end organ damage that can be attributed to the underlying plasma cel l 
proliferative disorder, speciﬁcally:  
o Hypercalcaemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of 
normal (ULN) or >2.75 mmol/L (>11 mg/dL) 
o Renal insufficiency: creatinine clearance <40 mL per min† or serum creatinine 
>177 μmol/L ( >2 mg/dL)  
o Anemia: hemoglobin value of >20 g/L below the lower limit of normal, or a hemoglobin 
value <100 g/L 
o Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized 
tomography ( CT), or PET- CT‡ 
• Any one or more of the following biomarkers of malignancy: 
o Clonal bone marrow plasma cell percentage* ≥60%  
o Involved:uninvolved serum free light chain ratio§ ≥100 
o >1 focal lesions on magnetic resonance imaging (MRI) studies¶ 
 
PET-CT=18F-ﬂuorodeoxyglucose positron emission tomography with com puted tomography .  
*Clonality should be established by showing κ/λ -light-chain restriction on ﬂow cytometry, immunohistochemistry, 
or immunoﬂuorescence. Bone marrow plasma cell percentage should preferably be estimated from a core 
biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used.  
†Measured or estimated by validated equations.  
‡If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to distinguish from 
solitar y plasmacytoma with minimal marrow involvement.  
§These values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The involved free 
light chain must be ≥100 mg/L.  
¶Each focal lesion must be 5 mm or more in size.  
Source:  Rajkumar et al, 2014.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 88 of 111 Appendix 4 Organ Response and Progression Criteria  
Organ Response  Progression 
Heart /Cardiaca NT-proBNP response (>30% and 
>300 ng/L decrease in subject s with 
baseline NT -proBNP ≥650 ng/L)  
OR 
NYHA class response (≥2 class decrease 
in subjects with baseline NYHA class III or IV) NT-proBNP progression (>30% 
and >300 ng/L increase)
b  
Kidney/ Renalc  ≥30% decrease in proteinuria or drop of proteinuria below 0.5 g/24 hours in the absence of renal progression  ≥25% decrease in eGFR  
Peripheral 
Nerved NIS-LL increase from baseline of <2 
points NIS-LL increase from baseline of 
≥2 points 
Liver /Hepatica 50% decrease in  abnormal ALP value ≥50% increase in ALP above  the 
lowest value 
Abbreviati ons: ALP  = alkaline phosphatase; eGFR = estimated glomerular filtration rate; NIS -LL = Neuropathy Impairment 
Score– Lower Limbs ; NT-proBNP = N-terminal pro -brain  natriuretic peptide; NYHA  = New York Heart Association.  
a Modified from Table 2 in Comenzo et al, 2012 . In addition to the progression criteria listed above, the investigators will use 
their best clinical judgment in circumstances that do not meet the specifically referenced criteria above in assessing the 
progression. A repeated assessment at an interval that is determined by the investigator is required to confirm the 
progression.  
b Subject s with progressively worsening renal function cannot be scored for NT -proBNP progression.  
c Palladini et al, 2014 . 
d Coelho et al, 2012.  
  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 89 of 111 Appendix 5 Neuropathy Impairment Scale – Lower Limbs  
 
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 90 of 111 
Appendix 6 Visual Analog Scale – Pain Intensity (VASPI)  
 
  
 
VISUAL ANALOG SCALE – PAIN INTENSITY 
 
 
 
 
 
 
Over the last week, on average, my lower extremity pain would be described as: 
 
 
 
 
 
 
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 91 of 111 Appendix 7 Eastern Cooperative Oncology Group (ECOG) Performance Status 
Grade  Description  
0 Fully  active, able to carry on all pre- disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours. 
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours. 
4 Completely disabled. Cannot carry on any self- care. Totally confined to bed or 
chair.  
5 Dead  
Source:  Oken et al, 1982 . 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 92 of 111 Appendix 8 New York Heart Association (NYHA) Functional Classification  
NYHA Class  Symptoms  
I No symptoms and no limitation in ordinary physical activity, e.g. shortness of 
breath when walking, climbing stairs etc.  
II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 
III Marked limitation in activity due to symptoms, even during le ss-than-
ordinary activity, e.g. walking short distances (20–100 m). Comfortable only at rest.  
IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. 
Source:  American Heart Association, 2015.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 93 of 111 Appendix 9 Short Form-36v2 Health Survey  
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 94 of 111  

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 95 of 111  
  

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 96 of 111  

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 97 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 98 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 99 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 100 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 101 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 102 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 103 of 111  
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 104 of 111 Appendix 10 Kansas City Cardiomyopathy Questionnaire (KCCQ) 
 

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 105 of 111  

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 106 of 111   

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 107 of 111  
  

Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 108 of 111 Appendix 11 Laboratory Tests 
Serum Chemistry:  
• ALP  (E)a 
• ALT (E)  
• AST (E)  
• Bilirubin - total  (E) and direct  
• GGT  
• BUN 
• LDH  
• Creatinine (E)  
• Glucose  
• Cholesterol  
• Triglycerides  
• Calcium  
• Phosphate  
• Protein - total 
• Albumin  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Magnesium  
• Amylase  
• Crea tine kinase  
• Uric acid  
• Estimated glomerular filtration rate (E)e 
• Estimated creatinine clearance  
• Cystatin C  Hematology:  
• Hemoglobin (E)  
• Hematocrit  
• RBC  
• WBC  
• Neutrophils (absolute [E], %)  
• Lymphocytes (absolute, %)  
• Monocytes (absolute, %)  
• Eosinophils (absolute, %)  
• Basophils (absolute, %)  
• Platelet count (E)  
Otherb: 
• Serum anti -NEOD001 antibodiesc 
• Serum NEOD001 concentration  
• Serum FLCsd 
• 24-hr urine protein excretion & total volume  
• Serum & 24 -hr urine PEP  
• Serum & urine IFE  
Inflammatory Biomarkersb: 
• IL-6 
• IL-8 
• TNF -alpha  
• INF-gamma  
• Complements C3, C4, and CH50 
• CRP  
• SAA (A- SAA)  
• Tryptase  
Urinalysis  - Dipstick:  
• Color & clarity  
• Specific gravity  
• pH 
• Protein  
• Glucose  
• Ketones  
• Bilirubin  
• Urobilinogen  
• Blood  
• Nitrite  
• Leukocyte esterase 
• Microscopic  Urinalysis  - Quantitative 
Analysis/Renal Biomarkersf: 
• Urine albumin/creatinine 
ratio 
• Urine NGAL  
• Urine RBP  Cardiac Biomarkers:  
• Troponin T  
• NT-proBNP  
Coagulation:  
• PT/INR  
• PTT 
• Additional indices - see Appendix 12  
Women of childbearing potential only:  
• Serum  beta hCG pregnancy tests (E)  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; A -SAA  = acute phase serum amyloid  A; AST   = aspartate 
aminotransferase; BUN  = blood urea nitrogen; CRP  = C- reactive protein; (E) = may be used for eli gibility; FLCs = free light chains; 
GGT  = gamma -glutamyl transpeptidase; hCG  = human chorionic gonadotropin; IFE  = immunofixation electrophoresis; IL  = interleukin; 
INF = interferon; LDH  = lactate dehydrogenase; NGAL  = neutrophil gelatinase -associated lipo calin; NT -proBNP  = N- terminal pro -
brain  natriuretic peptide; PEP  = protein electrophoresis; PT/INR  = prothrombin time/international normalized ratio; PTT  = partial 
thromboplastin time; RBC  = red blood cell; RBP  = retinol -binding protein; SAA  = serum amyloi d A; TNF = tumor necrosis factor; 
WBC  = white blood cell.  
a Including isozymes for subjects with ALP >5 × upper limit of normal.  
b See details in Section  5.4.2  regarding collection of samples in cases of suspe cted systemic infusion- related/hypersensitivity reactions.  
c Any sample found to be confirmed positive for anti -NEOD001 antibodies may be further evaluated by a neutralizing antibody  assay.  
d Including dFLC (difference between involved and uninvolved FLCs)  and FLC ratio. 
e GFR = 141 × min (Scr /κ, 1)α × max(Scr /κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black]  where: Scr = serum creatinine in 
mg/dL; κ = 0.7 for females, 0.9 for males; α = - 0.329 for females, - 0.411 for males; min = the minimum of Scr /κ or 1;  m ax = the 
maximum of Scr /κ or 1.  
f It is important that the sample be taken before exercising and at approximately the same time for each collection; therefore,  the first 
morning void is recommended. Urine samples to be collected and frozen for potential f uture analysis.  
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 109 of 111 Appendix 12 Coagulation Indices 
At Screening, EOS/ETD, and as clinically indicated , citrated plasma samples will be collected 
and frozen for potential analysis of coagulation indices at a later date; these analys es may 
include, but may not be limited to, the indices listed in the following table : 
Test Name  
Antithrombin Activity (ATIII Activity)  Fibrinogen Antigen 
Partial Thromboplastin Time Mixing Studies  High -Molecular Weight Kininogen  
D-dimer, quantitative Prekallikrein  
Euglobulin Lysis Time  Plasminogen Activator Inhibitor-1 Antigen 
Factor II Activity  Plasminogen Activator Inhibitor- 1 Activity  
Factor V Activity  Plasmin -antiplasmin Complex 
Factor VII Activity  Plasminogen Activity  
Factor VIII Activity  Protein C Activity  
Factor VIII Antigen Quantitation  Protein S Antigen Free  
Factor IX Activity  Thrombin Time 
Factor X Activity  Tissue Plasminogen Activator Activity  
Factor XI Activity  Tissue Plasminogen Activator Antigen  
Factor XII Activity  von Willebrand Factor Activity (Ristocetin 
Cofactor) 
Factor XIII Activity  von Willebrand Factor Antigen  
Fibrin Monomer von Willebrand Factor Multimers  
Fibrinogen Activity   
 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 110 of 111 Appendix 13 Schedule Of Events For Subjects Who Discontinue Study Drug Early but 
Agree to Return For Assessments After the ETD Visit   
 Assessment or Procedure Monthly  
Day 1 (±5 days)1 Every 3 Months after 
Last Visit  Clinical  Prior/Concomitant Medications/Therapy  X  
Adverse Event Assessment  X  
Physical Exam2 X  
Vital Signs3 X  
ECOG PS/NYHA Class4 X  
NIS-LL & VASPI5 X  
SF-36v26 X  
KCCQ7 X  
6MWT8,9 X (Months 3, 6, 9, 12 )  
Echocardiogram10 X (Month 12 )  
ECG (12 -lead triplicate)11 X (Months 3, 6, 9, 12)   Laboratory16 Hematology & Chemistry (including amyl ase and 
creatine kinase)12 X  
Coagulation13 X  
Inflammatory Biomarkers14 X (Month 3 )15  
Troponin T  X  
NT-proBNP8 X  
Pregnancy (WOCBP)  X17  
Serum Free Light Chain  X (Months 3, 6, 9, 12)   
Serum IFE & PEP  X (Months 3, 6, 9, 12)   
Urinalysis – Dipstick18 X (Months 3, 6, 9, 12)   
Urinalysis - Quantitative/Renal Biomarkers19 X (Months 3, 6, 9, 12)   
24-hour Urine Collection:    
Urine IFE & PEP  X (Months 3, 6, 9, 12)   
Urine Protein Excretion  X (Months 3, 6, 9, 12)   Other  Anti-NEOD001 Serum Sa mple  X20  
Vital Status Phone Call   X21 
Study Drug: N EOD001 CONFIDENTIAL  
Study Protocol: NEOD001 -201 Amendment 3 
 
Date:  22 October 2017 Page 111 of 111 BP = blood pressure; ECG  = electrocardiogram; ECOG PS  = Eastern Cooperative Oncology Group performance 
status; ETD  = Early Treatment Discontinuation; HR  = heart rate; IFE = immunofixation electrophoresis; 
KCCQ  = Kansas City Cardiomyopathy Questionnaire; NIS -LL = neuropathy impairment score – lower 
limbs;  NT-proBNP  = N- terminal pro -brain  natriuretic peptide; NYHA  = New York Heart Association; 
PEP = protein electrophoresis; RR  = respiratory rate; 6MWT = 6- minute walk test; SF -36v2 = Short Form -
36v2® Health Survey; VASP I  = visual analog scale – pain intensity; WOCBP  = women of childbearing 
potential.  
1. Study visits will occur every 28 days based on scheduling from Month 1 -Day 1. A ±5 -day window is allowed 
for visits start ing after Month 1. If a subject discontinues study drug prior to the end of the study, but is willing 
to continue to participate in study visits, the subject should have an ETD Visit per Table 1 and Section 6.2 and 
then have assessments performed monthly, through Month 12, if willing. The most important visit is the 
Month 12 -Day 1 Visit, so if a subject is unwilling to continue monthly visits, every effort should be made for 
the subject to return and complete th e Month 12 -Day 1 Visit on schedule. All visits after the ETD Visit should 
occur on schedule, that is, at the time when the visit would have occurred had the subject remained on study drug. An EOS Visit will not be conducted.  
2. Conduct a directed physical exa mination, including weight, and the components of the exam as clinically 
indicated. Assess macroglossia, submandibular nodes/fullness, adenopathy, ecchymoses, liver/spleen size (palpable  +/-), ascites (+/ -), and edema (which should be quantified on a scale of 0 -4). 
3. Vital signs include HR, RR, BP, and body temperature; assess any time during visit after subject has been at rest ≥5 minutes.  
4. See Appendix 7 (ECOG) and  Appendix 8 (NYHA).  
5. See Appendix 5 (NIS-LL; for all subjects with peripheral neuropathy at Screening ) and  Appendix 6  (VASPI; 
for subjects with painful peripheral neuropathy at Screening ). 
6. See Appendix 9;  SF-36v2  should be administered before performing any other study assessments on the same 
calendar day it is administered.  
7. See Appendix 10;  administer KCCQ after the SF -36v2 , but before conducting any other assessments on the 
same calendar day it is administered.  
8. NT-proBNP should be drawn before conducting 6MWT if being performed on the same calendar day.  
9. Collect BP and HR pre - and post -6MWT administration.  
10. Perform echocardiogram locally within 10  days before Day  1.  
11. Perform ECGs centrally any time during visit.  
12. Hematology and chemistry per  Appendix 11.  
13. Collect PT/INR and PTT monthly. Collect citrated plasma samples as clinically indicated  for freezing and for 
potential analysis of coagulation indices  at a later date; these analyses may include, but may not be limited to, 
the indices listed in  Appendix 12. 
14. Inflammatory biomarkers per  Appendix 11.  
15. Collect additional samples as clinically indica ted, such as when significant toxicity occurs per Section  5.4.2 . 
16. All laboratory tests to be done centrally, unless otherwise noted. Please refer to Laboratory Manual for details.  
17. Obtain local laboratory serum pregnancy test 90 (±5) days after the last study drug administration .  
18. Per Appendix 11.  
19. Per Appendix 11 . It is important that the sample be taken before exercising and at approximately the same tim e 
for each collection; therefore, the first morning void is recommended. Urine samples will be collected and frozen for potential analysis at a later date.  
20. Anti-NEOD001 serum samples: Collect if an earlier sample established the presence of anti -NEOD001 
antibodies or if a subject discontinued treatment due to a suspected immunologic reaction.  
21. For randomized subjects who received at least 1 dose of study drug,  conduct vital status telephone call 
approximately 3 months after last visit and approximately every 3 months thereafter or until subject enrolls in 
a separate open -label study, death, or for up to 5 years . 
 